1
|
Ding SY, Zhang QW, Guo DF, Feng B, Zheng H, Lu XP. [A case of a syndrome characterized by short stature, and developmental delay caused by heterozygous variation in the FOXP4 gene]. Zhonghua Er Ke Za Zhi 2024; 62:571-573. [PMID: 38763881 DOI: 10.3760/cma.j.cn112140-20231117-00379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 05/21/2024]
Affiliation(s)
- S Y Ding
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - Q W Zhang
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - D F Guo
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - B Feng
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - H Zheng
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - X P Lu
- Pediatric Hospital of the First Affiliated Hospital of Henan University of Chinese Medicine College of Pediatrics Henan University of Chinese Medicine, Zhengzhou 450000, China
| |
Collapse
|
2
|
Ma X, Chen ZH, Zhang HT, He RX, Wang Q, Ding Y, Song JQ, Jin Y, Li MQ, Dong H, Zhang Y, Lu M, Lu XP, Cao HQ, Wang YQ, Chen YX, Zheng H, Yang YL. [Clinical features and follow-up study on 55 patients with adolescence-onset methylmalonic acidemia]. Zhonghua Er Ke Za Zhi 2024; 62:520-525. [PMID: 38763872 DOI: 10.3760/cma.j.cn112140-20240130-00083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/21/2024]
Abstract
Objective: To investigate the clinical features and outcomes of adolescence-onset methylmalonic acidemia (MMA) and explore preventive strategies. Methods: This was a retrospective case analysis of the phenotypes, genotypes and prognoses of adolescence-onset MMA patients. There were 55 patients diagnosed in Peking University First Hospital from January 2002 to June 2023, the data of symptoms, signs, laboratory results, gene variations, and outcomes was collected. The follow-ups were done through WeChat, telephone, or clinic visits every 3 to 6 months. Results: Among the 55 patients, 31 were males and 24 were females. The median age of onset was 12 years old (range 10-18 yearsold). They visited clinics at Tanner stages 2 to 5 with typical secondary sexual characteristics. Nine cases (16%) were trigged by infection and 5 cases (9%) were triggered by insidious exercises. The period from onset to diagnosis was between 2 months and 6 years. Forty-five cases (82%) had neuropsychiatric symptoms as the main symptoms, followed by cardiovascular symptoms in 12 cases (22%), kidney damage in 7 cases (13%), and eye disease in 12 cases (22%). Fifty-four cases (98%) had the biochemical characteristics of methylmalonic acidemia combined with homocysteinemia, and 1 case (2%) had the isolated methylmalonic acidemia. Genetic diagnosis was obtained in 54 cases, with 20 variants identified in MMACHC gene and 2 in MMUT gene. In 53 children with MMACHC gene mutation,1 case had dual gene variants of PRDX1 and MMACHC, with 105 alleles. The top 5 frequent variants in MMACHC were c.482G>A in 39 alleles (37%), c.609G>A in 17 alleles (16%), c.658_660delAAG in 11 alleles (10%), c.80A>G in 10 alleles (10%), c.567dupT and c.394C>T both are 4 alleles (4%). All patients recovered using cobalamin, L-carnitine, betaine, and symptomatic therapy, and 54 patients (98%) returned to school or work. Conclusions: Patients with adolescence-onset MMA may triggered by fatigue or infection. The diagnosis is often delayed due to non-specific symptoms. Metabolic and genetic tests are crucial for a definite diagnosis. Treatment with cobalamin, L-carnitine, and betaine can effectively reverse the prognosis of MMA in adolescence-onset patients.
Collapse
Affiliation(s)
- X Ma
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - Z H Chen
- Scientific research and innovation center, Women and Children's Hospital, Xiamen University, Xiamen 361000, China
| | - H T Zhang
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - R X He
- Department of Respiratory Medicine Ⅱ, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - Q Wang
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - Y Ding
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - J Q Song
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - Y Jin
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - M Q Li
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - H Dong
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - Y Zhang
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| | - M Lu
- Department of Pediatrics, Women and Children's Hospital, Xiamen University, Xiamen 361000, China
| | - X P Lu
- Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - H Q Cao
- Department of Pediatrics, Baoding Maternal and Child Health Hospital, Baoding 071023, China
| | - Y Q Wang
- Department of Pediatrics, Baoding Maternal and Child Health Hospital, Baoding 071023, China
| | - Y X Chen
- Department of Endocrinology, Genetics and Metabolism, Henan Children's Hospital, Zhengzhou 451161, China
| | - H Zheng
- Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China
| | - Y L Yang
- Children's Medical Center, Peking University First Hospital, Beijing 102600, China
| |
Collapse
|
3
|
Wang TH, Li HX, Li BL, Zheng H, Yan T. [Impact of obesity on the incidence of postoperative pulmonary complications following laparoscopic colorectal surgery]. Zhonghua Yi Xue Za Zhi 2024; 104:1610-1616. [PMID: 38742348 DOI: 10.3760/cma.j.cn112137-20230810-00191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/16/2024]
Abstract
Objective: To evaluate the effects of obesity on the incidence of postoperative pulmonary complications (PPCs) following laparoscopic colorectal surgery. Methods: A total of 150 patients with pathological diagnosis of colorectal cancer who accepted laparoscopic colorectal excision from January to May 2023 were retrospectively recruited. All the patients scored 26 points or more in the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) model, making them all in intermediate to high risks of PPCs. Patients were divided into obesity group and non-obesity group depending on whether they were obese or not. Propensity score matching (1∶1) was performed to achieve the balance of clinicopathological characteristics with the matching factors of age, sex, respiratory complications and ARISCAT score. A total of 96 patients were eventually enrolled, with 48 patients in obesity group and 48 patients in non-obesity group. Besides, the patients were divided into 25°-30° Trendelenburg subgroup and ±10°-15° Trendelenburg subgroup according to surgical sites for further analysis. The incidence of PPCs, the intraoperative airway pressure and blood biomarker expression of lung injury, including soluble receptor for advanced glycation end products (sRAGE) and angiopoietin-2 (ANG2) at postoperative day (POD) 1 and POD3 between the two groups were compared. The relationship between obesity and incidence of PPCs within 30 postoperative days were analyzed with unifactorial Cox proportional hazard model. Results: The obesity group was comprised of 35 males and 13 females with a median age of 60 (49, 69) years, and the non-obesity group was comprised of 35 males and 13 females with a median age of 60 (52, 67) years. The incidence of PPCs was 50.0% (24/48) in the obesity group, which was higher than 20.8% (10/48) in the non-obesity group and the incidence of grade Ⅰ PPCs and microatelectasis were 31.3% (15/48) and 33.3% (16/48), higher than the 12.5% (6/48) and 12.5% (6/48) of the non-obesity group (all P<0.05). The peak airway pressure (Ppeak) and plateau airway pressure (Pplat) of patients in obesity group were 34.0(31.5, 36.5) and 30.0(27.0, 32.0) cmH2O(1 cmH2O=0.098 kPa), which were significantly higher than the 26.0 (24.0, 29.5) and 22.0 (21.0, 26.5) cmH2O of the non-obesity group (all P<0.001). The ANG2 level of the obesity group at POD3 was 11.9 (8.4, 16.5) μg/L, which was higher than 9.2 (6.0, 12.3) μg/L of the non-obesity group (P=0.045). In 25°-30°Trendelenburg subgroup, the incidence of PPCs in obese patients were significantly higher than that of non-obese patients [41.4% (12/29) vs 11.4% (4/35), P=0.005]. In ±10°-15°Trendelenburg subgroup, no significant difference was found in PPCs incidence between obese and non-obese patients [63.2% (12/19) vs 46.2% (6/13), P=0.215]. The unifactorial Cox proportional hazard model analysis showed that obesity was a risk factor of PPCs in 30 postoperative days (HR=3.015, 95%CI: 1.438-6.321, P=0.001). Conclusion: In patients undergoing laparoscopic colorectal surgery with intermediate to high risk of PPCs, obesity raises intraoperative airway pressure and aggravates intraoperative lung endothelial injury. Obesity is a risk factor of PPCs in 30 postoperative days.
Collapse
Affiliation(s)
- T H Wang
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H X Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - B L Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H Zheng
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Yan
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
4
|
Jost D, Huang HY, Rossi M, Singh A, Huang DJ, Lee Y, Zheng H, Mitchell JF, Moritz B, Shen ZX, Devereaux TP, Lee WS. Low Temperature Dynamic Polaron Liquid in a Manganite Exhibiting Colossal Magnetoresistance. Phys Rev Lett 2024; 132:186502. [PMID: 38759205 DOI: 10.1103/physrevlett.132.186502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 03/04/2024] [Accepted: 04/01/2024] [Indexed: 05/19/2024]
Abstract
Polarons-fermionic charge carriers bearing a strong companion lattice deformation-exhibit a natural tendency for self-localization due to the recursive interaction between electrons and the lattice. While polarons are ubiquitous in insulators, how they evolve in transitions to metallic and superconducting states in quantum materials remains an open question. Here, we use resonant inelastic x-ray scattering to track the electron-lattice coupling in the colossal magneto-resistive bi-layer manganite La_{1.2}Sr_{1.8}Mn_{2}O_{7} across its metal-to-insulator transition. The response in the insulating high-temperature state features harmonic emissions of a dispersionless oxygen phonon at small energy transfer. Upon cooling into the metallic state, we observe a drastic redistribution of spectral weight from the region of these harmonic emissions to a broad high energy continuum. In concert with theoretical calculations, we show that this evolution implies a shift in electron-lattice coupling from static to dynamic lattice distortions that leads to a distinct polaronic ground state in the low temperature metallic phase-a dynamic polaron liquid.
Collapse
Affiliation(s)
- D Jost
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - H-Y Huang
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - M Rossi
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - A Singh
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
- Department of Physics and Astrophysics, University of Delhi, New Delhi 110007, India
| | - D-J Huang
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - Y Lee
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - H Zheng
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J F Mitchell
- Materials Science Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - B Moritz
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
| | - Z-X Shen
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
- Department of Physics, Stanford University, Stanford, California 94305, USA
- Department of Applied Physics, Stanford University, Stanford, California 94305, USA
- Geballe Laboratory for Advanced Materials, Stanford University, Stanford, California 94305, USA
| | - T P Devereaux
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
- Department of Materials Science and Engineering, Stanford University, Stanford, California 94305, USA
- Geballe Laboratory for Advanced Materials, Stanford University, Stanford, California 94305, USA
| | - W-S Lee
- Stanford Institute for Materials and Energy Sciences (SIMES), 2575 Sand Hill Road, Menlo Park, California 94025, USA
| |
Collapse
|
5
|
Liu G, Shu W, Chen Y, Fu Y, Fang S, Zheng H, Cheng W, Lin Q, Hu Y, Jiang N, Yu B. Bone-derived PDGF-BB enhances hippocampal non-specific transcytosis through microglia-endothelial crosstalk in HFD-induced metabolic syndrome. J Neuroinflammation 2024; 21:111. [PMID: 38685040 PMCID: PMC11057146 DOI: 10.1186/s12974-024-03097-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 04/10/2024] [Indexed: 05/02/2024] Open
Abstract
BACKGROUND It is well known that high-fat diet (HFD)-induced metabolic syndrome plays a crucial role in cognitive decline and brain-blood barrier (BBB) breakdown. However, whether the bone-brain axis participates in this pathological process remains unknown. Here, we report that platelet-derived growth factor-BB (PDGF-BB) secretion by preosteoclasts in the bone accelerates neuroinflammation. The expression of alkaline phosphatase (ALPL), a nonspecific transcytosis marker, was upregulated during HFD challenge. MAIN BODY Preosteoclast-specific Pdgfb transgenic mice with high PDGF-BB concentrations in the circulation recapitulated the HFD-induced neuroinflammation and transcytosis shift. Preosteoclast-specific Pdgfb knockout mice were partially rescued from hippocampal neuroinflammation and transcytosis shifts in HFD-challenged mice. HFD-induced PDGF-BB elevation aggravated microglia-associated neuroinflammation and interleukin-1β (IL-1β) secretion, which increased ALPL expression and transcytosis shift through enhancing protein 1 (SP1) translocation in endothelial cells. CONCLUSION Our findings confirm the role of bone-secreted PDGF-BB in neuroinflammation and the transcytosis shift in the hippocampal region during HFD challenge and identify a novel mechanism of microglia-endothelial crosstalk in HFD-induced metabolic syndrome.
Collapse
Affiliation(s)
- Guanqiao Liu
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Wen Shu
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Department of Trauma Orthopedics, Liuzhou People's Hospital, Liuzhou, China
| | - Yingqi Chen
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yong Fu
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Trauma Center, Department of Orthopaedic Trauma, The Second Affiliated Hospital of Hengyang Medical College, South China University, Hengyang, China
| | - Shuai Fang
- Trauma Center, Department of Orthopaedic Trauma, The Second Affiliated Hospital of Hengyang Medical College, South China University, Hengyang, China
| | - Haonan Zheng
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Weike Cheng
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Qingrong Lin
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Yanjun Hu
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Nan Jiang
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
| | - Bin Yu
- Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
| |
Collapse
|
6
|
Cheng YZ, Lian XR, Li HX, Wang TH, Zheng H, Yan T. [Relationship between gut microbiota and its metabolite dysregulation and postoperative cognitive dysfunction in elderly male C57BL/6J mice after laparotomy exploration]. Zhonghua Yi Xue Za Zhi 2024; 104:1316-1322. [PMID: 38637168 DOI: 10.3760/cma.j.cn112137-20230810-00199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/20/2024]
Abstract
Objective: To explore the relationship between gut microbiota and its metabolite dysregulation and postoperative cognitive dysfunction in elderly male C57BL/6J mice after laparotomy exploration. Methods: A total of 48 specific pathogen-free (SPF) male C57BL/6J mice, aged 16-17 months, were divided into two groups by random number table method: control group (n=24) and operation group (n=24). Mice in the operation group were induced with 1.4% isoflurane for 15 minutes, followed by a 10 minutes exploratory laparotomy anesthetized with 1.4% isoflurane and 100% oxygen, and anesthesia continued for 2 hours after surgery. Mice in control group were put in 100% oxygen for 2 hours. Feces and venous blood samples of both groups were collected 48 hours after surgery. Changes in the abundance and diversity of intestinal bacteria in the feces were detected by 16S rDNA gene sequencing. Functional changes of fecal metabolic profiles were detected by liquid chromatography tandem mass spectrometry (LC/MS) metabolomics and differential metabolite functions were analyzed. The serum level of interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) were detected by Enzyme-linked immunosorbent assay (ELISA). The cognitive function of the mice was detected by Morris water maze test 3 days after operation. Results: The postoperative escape latency of mice in control group and operation group was (22.0±4.9) and (35.0±5.1) s, and the target quadrant residence time was (26.0±3.7) and (16.0±2.9) s, respectively. Compared with the control group, the postoperative escape latency of mice in the operation group was prolonged (P=0.035), and the residence time in the target quadrant was reduced (P=0.006). The difference of intestinal flora between the two groups was comparable. The expression levels of Escherichia coli, shigella and clostridium in the operation group were up-regulated, while the expression levels of rumen bacteria and butyricobacteria were down-regulated. Fecal metabolic profiles of mice in control group and operation group were obtained by LC/MS, and 14 and 21 different metabolites were screened in positive and negative ion modes, respectively. The different metabolites in positive ion mode were glutamic acid, 2-indoleic acid, kynuuric acid and glyceraldehyde. The negative ion pattern differential metabolites are methionine, aspartic acid, L-threonine, tyrosyl-threonine and 5-hydroxyindole-3-acetic acid. The identified differential metabolite pathways are mainly involved in amino acid, fatty acid and tryptophan metabolism and nucleotide synthesis. There were no significant differences in serum levels of IL-1β, IL-6 and TNF-α between the two groups (all P>0.05). Conclusion: The dysregulated changes of gut microbiota and its metabolites are correlated with the occurrence of postoperative cognitive dysfunction in elderly male C57BL/6J mice. Anesthesia and surgery alter the structure of mice intestinal bacteria on the level of abundance, and change the metabolic balance and feces metabolomic phenotype.
Collapse
Affiliation(s)
- Y Z Cheng
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - X R Lian
- Department of Radiotherapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H X Li
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T H Wang
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H Zheng
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Yan
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
7
|
Li HX, Xu X, Tan PX, Wang TH, Li BL, Zheng H, Yan T. [The effect of deep neuromuscular block combined with low pneumoperitoneum pressure on postoperative pain in patients undergoing laparoscopic radical colorectal surgery]. Zhonghua Yi Xue Za Zhi 2024; 104:1057-1063. [PMID: 38561301 DOI: 10.3760/cma.j.cn112137-20231011-00704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Objective: To investigate the effect of deep neuromuscular blockade (DNMB) combined with low pneumoperitoneum pressure anesthesia strategy on postoperative pain in patients undergoing laparoscopic colorectal surgery. Methods: This study was a randomized controlled trial. One hundred and twenty patients who underwent laparoscopic colorectal surgery at Cancer Hospital of Chinese Academy of Medical Sciences from December 1, 2022 to May 31, 2023 were selected and randomly divided into two groups by random number table method. Moderate neuromuscular blockade [train of four stimulations count (TOFC)=1-2] was maintained in patients of the control group (group C, n=60) and pneumoperitoneum pressure level was set at 15 mmHg(1 mmHg=0.133 kPa). DNMB [post-tonic stimulation count (PTC)=1-2] was maintained in patients of the DNMB combined with low pneumoperitoneum pressuregroup (group D, n=60) and pneumoperitoneum pressure level was set at 10 mmHg. The primary measurement was incidence of moderate to severe pain at 1 h after surgery. The secondary measurements the included incidence of moderate to severe pain at 1, 2, 3, 5 d and 3 months after surgery, the incidence of rescue analgesic drug use, the doses of sufentanil in analgesic pumps, surgical rating scale (SRS) score, the incidence of postoperative residual neuromuscular block, postoperative recovery [evaluated with length of post anesthesia care unit (PACU) stay, time of first exhaust and defecation after surgery and length of hospital stay] and postoperative inflammation conditions [evaluated with serum concentration of interleukin (IL)-1β and IL-6 at 1 d and 3 d after surgery]. Results: The incidence of moderate to severe pain in group D 1 h after surgery was 13.3% (8/60), lower than 30.0% (18/60) of group C (P<0.05). The incidence of rescue analgesia in group D at 1 h and 1 d after surgery were 13.3% (8/60) and 4.2% (5/120), respectively, lower than 30.0% (18/60) and 12.5% (15/120) of group C (both P<0.05). The IL-1β level in group D was (4.1±1.8)ng/L at 1 d after surgery, which was lower than (4.9±2.6) ng/L of group C (P=0.048). The IL-6 level in group D was (2.0±0.7)ng/L at 3 d after surgery, which was lower than (2.4±1.1) ng/L of group C (P=0.018). There was no significant difference in the doses of sufentanil in analgesic pumps, intraoperative SRS score, incidence of neuromuscular block residue, time spent in PACU, time of first exhaust and defecation after surgery, incidence of nausea and vomiting, and length of hospitalization between the two groups (all P>0.05). Conclusion: DNMB combined with low pneumoperitoneum pressure anesthesia strategy alleviates the early-stage pain in patients after laparoscopic colorectal surgery.
Collapse
Affiliation(s)
- H X Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - X Xu
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - P X Tan
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T H Wang
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - B L Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H Zheng
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Yan
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
8
|
Zhang HT, Ma X, Jin Y, Li MQ, Song JQ, Chen ZH, Liu Y, Lu XP, Zheng H, Yang YL. [Analysis of 9 patients with adolescence-onset methylenetetrahydrofolate reductase deficiency]. Zhonghua Er Ke Za Zhi 2024; 62:357-362. [PMID: 38527507 DOI: 10.3760/cma.j.cn112140-20230919-00200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/27/2024]
Abstract
Objective: To explore the diagnosis and treatment of adolescence-onset methylenetetrahydrofolate reductase (MTHFR) deficiency. Methods: This was a retrospective case study. Nine patients with adolescence-onset MTHFR deficiency were diagnosed at Peking University First Hospital from January 2016 to December 2022, and followed up for more than 1 year. Their general information, clinical manifestations, laboratory tests, cranial images, MTHFR gene variants, diagnosis, treatment, and outcome were analyzed retrospectively. Results: The 9 patients came from 8 families. They had symptoms at age of 8.0 years to 17.0 years and diagnosed at 9.0 years to 17.5 years. Eight were male and 1 was female. Two patients were brothers, the elder brother developed abnormal gait at 17.0 years; and the younger brother was then diagnosed at 15.0 years of age and treated at the asymptomatic stage, who was 18.0 years old with normal condition during this study. The main manifestations of the 8 symptomatic patients included progressive dyskinesia and spastic paralysis of the lower limbs, with or without intellectual decline, cognitive impairment and behavioral abnormalities. Totally, 15 variants of MTHFR gene were identified in the 9 patients, including 8 novel variants. Five patients had brain image abnormalities. Increased plasma total homocysteine level (65-221 μmol/L) was found in all patients, and decreased to 20-70 μmol/L after treatment with betaine and calcium folinate. Besides, the 8 symptomatic patients had their behavior and cognitive problems significantly improved, with a legacy of lower limb motor disorders. Conclusions: Late-onset MTHFR deficiency can occur in adolescence. The diagnosis is usually delayed because of non-specific clinical symptoms. The test of blood total homocysteine could be used as a selective screening test. Eight novel varients of MTHFR gene were identified. Timely treatment can improve clinical condition significantly, and pre-symptomatic treatment may prevent brain damage.
Collapse
Affiliation(s)
- H T Zhang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| | - X Ma
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| | - Y Jin
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| | - M Q Li
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| | - J Q Song
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| | - Z H Chen
- Department of Pediatrics, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen 361003, China
| | - Y Liu
- Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029, China
| | - X P Lu
- Department of Pediatrics, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450052, China
| | - H Zheng
- Department of Pediatrics, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450052, China
| | - Y L Yang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
| |
Collapse
|
9
|
Santos L, Zheng H, Singhal S, Wong M. Remifentanil for tracheal intubation without neuromuscular blocking drugs in adult patients: a systematic review and meta-analysis. Anaesthesia 2024. [PMID: 38403817 DOI: 10.1111/anae.16255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2024] [Indexed: 02/27/2024]
Abstract
There is increasing interest in the use of short-acting opioids such as remifentanil to facilitate tracheal intubation. The aim of this systematic review was to determine the efficacy and safety of remifentanil for tracheal intubation compared with neuromuscular blocking drugs in adult patients. We conducted a systematic search for randomised controlled trials evaluating remifentanil for tracheal intubation. Primary outcomes included tracheal intubation conditions and adverse events. Twenty-one studies evaluating 1945 participants were included in the analysis. Use of remifentanil (1.5-4.0 μg.kg-1 ) showed no evidence of a difference in tracheal intubation success rate compared with neuromuscular blocking drugs (risk ratio (95%CI) 0.97 (0.94-1.01); six studies; 1232 participants; I2 28%; p = 0.16; moderate-certainty evidence). Compared with neuromuscular blocking drugs, the use of remifentanil (2.0-4.0 μg.kg-1 ) makes little to no difference in terms of producing excellent tracheal intubation conditions (risk ratio (95%CI) 1.16 (0.72-1.87); two studies; 121 participants; I2 31%, p = 0.54; moderate-certainty of evidence). There was no evidence of an effect between remifentanil (2.0-4.0 μg.kg-1 ) and neuromuscular blocking drugs for bradycardia (risk ratio (95%CI) 0.44 (0.01-13.90); two studies; 997 participants; I2 81%; p = 0.64) and hypotension (risk ratio (95%CI) 1.05 (0.44-2.49); three studies; 1071 participants; I2 92%; p = 0.92). However, the evidence for these two outcomes was judged to be of very low-certainty. We conclude that remifentanil may be used as an alternative drug for tracheal intubation in cases where neuromuscular blocking drugs are best avoided, but more studies are required to evaluate the haemodynamic adverse events of remifentanil at different doses.
Collapse
Affiliation(s)
- L Santos
- Dental Anaesthesia, University of Toronto, Toronto, ON, Canada
| | - H Zheng
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada
| | - S Singhal
- Dental Public Health, University of Toronto, Toronto, ON, Canada
| | - M Wong
- Dental Anaesthesia, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
10
|
Lian B, Li Z, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Sheng X, Tian H, Si L, Chi Z, Wang X, Lai Y, Sun T, Zhang Q, Kong Y, Long GV, Guo J, Cui C. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol 2024; 35:211-220. [PMID: 37956739 DOI: 10.1016/j.annonc.2023.10.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 10/16/2023] [Accepted: 10/19/2023] [Indexed: 11/15/2023] Open
Abstract
BACKGROUND The outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial. It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we conducted this trial. PATIENTS AND METHODS This single-arm phase II trial enrolled patients with resectable mucosal melanoma. Patients received toripalimab 3 mg/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.) for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg/kg Q2W starting 2 ± 1weeks after surgery for 44 weeks. The primary endpoint was the pathologic response rate according to the International Neoadjuvant Melanoma Consortium recommendations. RESULTS Between August 2019 and October 2021, 29 patients were enrolled and received treatment, of whom 24 underwent resection. The median follow-up time was 34.2 months (95% confidence interval 20.4-48.0 months). The pathologic response rate was 33.3% (8/24; 4 pathological complete responses and 4 pathological partial responses). The median event-free survival for all patients was 11.1 months (95% confidence interval 5.3-16.9 months). The median overall survival was not reached. Neoadjuvant therapy was tolerable with 8 (27.5%) grade 3-4 treatment-related adverse events and no treatment-related deaths. Tissue samples of 17 patients at baseline and after surgery were collected (5 responders and 12 nonresponders). Multiplex immunohistochemistry demonstrated a significant increase in CD3+ (P = 0.0032) and CD3+CD8+ (P = 0.0038) tumor-infiltrating lymphocytes after neoadjuvant therapy, particularly in pathological responders. CONCLUSIONS Neoadjuvant toripalimab combined with axitinib in resectable mucosal melanoma demonstrated a promising pathologic response rate with significantly increased infiltrating CD3+ and CD3+CD8+ T cells after therapy.
Collapse
Affiliation(s)
- B Lian
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Z Li
- Department of Pathology, Peking University Cancer Hospital and Institute, Beijing
| | - N Wu
- Department of Thoracic Surgery, Peking University Cancer Hospital and Institute, Beijing
| | - M Li
- Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing
| | - X Chen
- Department of Otorhinolaryngology, Key Laboratory of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing
| | - H Zheng
- Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing
| | - M Gao
- Department of Gynecologic Oncology, Peking University Cancer Hospital and Institute, Beijing
| | - D Wang
- Peking University School of Stomatology, Beijing
| | - X Sheng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - H Tian
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - L Si
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Z Chi
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - X Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - Y Lai
- Department of Pathology, Peking University Cancer Hospital and Institute, Beijing
| | - T Sun
- The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China
| | - Q Zhang
- The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China
| | - Y Kong
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - G V Long
- Melanoma Institute of Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia
| | - J Guo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing
| | - C Cui
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing.
| |
Collapse
|
11
|
Zheng H, Wang YL. [Prioritizing the integrated management of cancer pain to comprehensively enhance the diagnosis and treatment proficiency in cancer pain]. Zhonghua Yi Xue Za Zhi 2024; 104:167-170. [PMID: 38220440 DOI: 10.3760/cma.j.cn112137-20230809-00188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/16/2024]
Abstract
As one of the most common complications of cancer or its treatment, cancer-related pain can negatively affect the functional status and quality of life of patients. Pain management for cancer patients in China started later than that in developed countries. After 30 years of efforts by health authorities and medical professionals, cancer pain management in China has made great progress. However, with the accelerated aging of the Chinese population, the increasing incidence of cancer, the prolonged survival of cancer patients, and the strengthening of people's expectations for high-quality life, there is still a gap between the development level of cancer pain management in China and the actual health needs of cancer patients. This article provides a comprehensive overview of the current state and future challenges facing the integrated management of cancer pain in China. Simultaneously, it offers a prospective outlook on future developments, thereby furnishing vital information for professionals engaged in the field of cancer pain management.
Collapse
Affiliation(s)
- H Zheng
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021,China
| | - Y L Wang
- Department of Anesthesiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021,China
| |
Collapse
|
12
|
Wang X, Zheng H, Yang B, Zu M, Wang Z, Zhang J, Zheng F, Yang M, Tong MCF, Zhao L, Bai W. Estrogen as a guardian of auditory health: Tsp1-CD47 axis regulation and noise-induced hearing loss. Climacteric 2023:1-11. [PMID: 38108225 DOI: 10.1080/13697137.2023.2287632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 12/18/2023] [Indexed: 12/19/2023]
Abstract
OBJECTIVES This study aimed to analyze the role of estrogen in noise-induced hearing loss (NIHL) and uncover underlying mechanisms. METHODS An ovariectomized Sprague-Dawley rat model (OVX) was constructed to investigate the hearing threshold and auditory latency before and after noise exposure using the auditory brainstem response (ABR) test. The morphological changes were assessed using immunofluorescence, scanning electron microscopy and transmission electron microscopy. Proteomics and bioinformatics were used to analyze the mechanism. The findings were further verified through western blot and Luminex liquid suspension chip technology. RESULTS After noise exposure, OVX rats exhibited substantially elevated hearing thresholds. A conspicuous delay in ABR wave I latency was observed, alongside increased loss of outer hair cells, severe collapse of stereocilia and pronounced deformation of the epidermal plate. Accordingly, OVX rats with estrogen supplementation exhibited tolerance to NIHL. Additionally, a remarkable upregulation of the thrombospondin 1 (Tsp1)-CD47 axis in OVX rats was discovered and verified. CONCLUSIONS OVX rats were more susceptible to NIHL, and the protective effect of estrogen was achieved through regulation of the Tsp1-CD47 axis. This study presents a novel mechanism through which estrogen regulates NIHL and offers a potential intervention strategy for the clinical treatment of NIHL.
Collapse
Affiliation(s)
- X Wang
- Department of Obstetrics and Gynecology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China
- National Clinical Research Center for Otolaryngologic Diseases, Beijing, China
- State Key Lab of Hearing Science, Ministry of Education, Beijing, China
| | - H Zheng
- National Clinical Research Center for Otolaryngologic Diseases, Beijing, China
- State Key Lab of Hearing Science, Ministry of Education, Beijing, China
- Senior Department of Otolaryngology-Head & Neck Surgery, Sixth Medical Center of PLA General Hospital, Beijing, China
| | - B Yang
- Peking University Fifth School of Clinical Medicine, Beijing Hospital, Beijing, China
| | - M Zu
- Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Z Wang
- Department of Obstetrics and Gynecology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China
| | - J Zhang
- Department of Obstetrics and Gynecology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China
| | - F Zheng
- National Clinical Research Center for Otolaryngologic Diseases, Beijing, China
- State Key Lab of Hearing Science, Ministry of Education, Beijing, China
- Senior Department of Otolaryngology-Head & Neck Surgery, Sixth Medical Center of PLA General Hospital, Beijing, China
| | - M Yang
- Department of Obstetrics and Gynecology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China
| | - M C F Tong
- Department of Otorhinolaryngology, Head and Neck Surgery, Chinese University of Hong Kong, Hong Kong, China
| | - L Zhao
- National Clinical Research Center for Otolaryngologic Diseases, Beijing, China
- State Key Lab of Hearing Science, Ministry of Education, Beijing, China
- Senior Department of Otolaryngology-Head & Neck Surgery, Sixth Medical Center of PLA General Hospital, Beijing, China
| | - W Bai
- Department of Obstetrics and Gynecology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China
| |
Collapse
|
13
|
Gao X, McFadden WM, Wen X, Emanuelli A, Lorson ZC, Zheng H, Kirby KA, Sarafianos SG. Use of TSAR, Thermal Shift Analysis in R, to identify Folic Acid as a Molecule that Interacts with HIV-1 Capsid. bioRxiv 2023:2023.11.29.569293. [PMID: 38076946 PMCID: PMC10705415 DOI: 10.1101/2023.11.29.569293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Thermal shift assay (TSA) is a versatile biophysical technique for studying protein interactions. Here, we report a free, open-source software tool TSAR (Thermal Shift Analysis in R) to expedite and automate the analysis of thermal shift data derived either from individual experiments or large screens of chemical libraries. The TSAR package incorporates multiple, dynamic workflows to facilitate the analysis of TSA data and returns publication-ready graphics or processed results. Further, the package includes a graphic user interface (GUI) that enables easy use by non-programmers, aiming to simplify TSA analysis while diversifying visualization. To exemplify the utility of TSAR we screened a chemical library of vitamins to identify molecules that interact with the capsid protein (CA) of human immunodeficiency virus type 1 (HIV-1). Our data show that hexameric CA interacts with folic acid in vitro.
Collapse
Affiliation(s)
- X. Gao
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - W. M. McFadden
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - X. Wen
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - A. Emanuelli
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - Z. C. Lorson
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - H. Zheng
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - K. A. Kirby
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| | - S. G. Sarafianos
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Children’s Healthcare of Atlanta, Atlanta, GA
| |
Collapse
|
14
|
Zheng H, Zhang C, Zhang J, Duan L. "Sentinel or accomplice": gut microbiota and microglia crosstalk in disorders of gut-brain interaction. Protein Cell 2023; 14:726-742. [PMID: 37074139 PMCID: PMC10599645 DOI: 10.1093/procel/pwad020] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 04/06/2023] [Indexed: 04/20/2023] Open
Abstract
Abnormal brain-gut interaction is considered the core pathological mechanism behind the disorders of gut-brain interaction (DGBI), in which the intestinal microbiota plays an important role. Microglia are the "sentinels" of the central nervous system (CNS), which participate in tissue damage caused by traumatic brain injury, resist central infection and participate in neurogenesis, and are involved in the occurrence of various neurological diseases. With in-depth research on DGBI, we could find an interaction between the intestinal microbiota and microglia and that they are jointly involved in the occurrence of DGBI, especially in individuals with comorbidities of mental disorders, such as irritable bowel syndrome (IBS). This bidirectional regulation of microbiota and microglia provides a new direction for the treatment of DGBI. In this review, we focus on the role and underlying mechanism of the interaction between gut microbiota and microglia in DGBI, especially IBS, and the corresponding clinical application prospects and highlight its potential to treat DGBI in individuals with psychiatric comorbidities.
Collapse
Affiliation(s)
- Haonan Zheng
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
- Beijing Key Laboratory for Helicobacter Pylori Infection and Upper Gastrointestinal Diseases, Beijing 100191, China
| | - Cunzheng Zhang
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
- Beijing Key Laboratory for Helicobacter Pylori Infection and Upper Gastrointestinal Diseases, Beijing 100191, China
| | - Jindong Zhang
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
- Beijing Key Laboratory for Helicobacter Pylori Infection and Upper Gastrointestinal Diseases, Beijing 100191, China
| | - Liping Duan
- Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
- Beijing Key Laboratory for Helicobacter Pylori Infection and Upper Gastrointestinal Diseases, Beijing 100191, China
| |
Collapse
|
15
|
Ma PF, Li S, Wang GZ, Jing XS, Liu DY, Zheng H, Li CH, Wang YS, Wang YZ, Wu Y, Zhan PY, Duan WF, Liu QQ, Yang T, Liu ZM, Jing QY, Ding ZW, Cui GF, Liu ZQ, Xia GS, Wang GX, Wang PP, Gao L, Hu DS, Zhang JL, Cao YH, Liu CY, Li ZY, Zhang JC, Li CZ, Li Z, Zhao YZ. [Safety of double and a half layered esophagojejunal anastomosis in radical gastrectomy: A prospective, multi-center, single arm trial]. Zhonghua Wei Chang Wai Ke Za Zhi 2023; 26:977-985. [PMID: 37849269 DOI: 10.3760/cma.j.cn441530-20230301-00058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/19/2023]
Abstract
Objective: To evaluate the safety of double and a half layered esophagojejunal anastomosis in radical gastrectomy. Methods: This prospective, multi-center, single-arm study was initiated by the Affiliated Cancer Hospital of Zhengzhou University in June 2021 (CRAFT Study, NCT05282563). Participating institutions included Nanyang Central Hospital, Zhumadian Central Hospital, Luoyang Central Hospital, First Affiliated Hospital of Henan Polytechnic University, First Affiliated Hospital of Henan University, Luohe Central Hospital, the People's Hospital of Hebi, First People's Hospital of Shangqiu, Anyang Tumor Hospital, First People's Hospital of Pingdingshan, and Zhengzhou Central Hospital Affiliated to Zhengzhou University. Inclusion criteria were as follows: (1) gastric adenocarcinoma confirmed by preoperative gastroscopy;(2) preoperative imaging assessment indicated that R0 resection was feasible; (3) preoperative assessment showed no contraindications to surgery;(4) esophagojejunostomy planned during the procedure; (5) patients volunteered to participate in this study and gave their written informed consent; (6) ECOG score 0-1; and (7) ASA score I-III. Exclusion criteria were as follows: (1) history of upper abdominal surgery (except laparoscopic cholecystectomy);(2) history of gastric surgery (except endoscopic submucosal dissection and endoscopic mucosal resection); (3) pregnancy or lactation;(4) emergency surgery for gastric cancer-related complications (perforation, hemorrhage, obstruction); (5) other malignant tumors within 5 years or coexisting malignant tumors;(6) arterial embolism within 6 months, such as angina pectoris, myocardial infarction, and cerebrovascular accident; and (7) comorbidities or mental health abnormalities that could affect patients' participation in the study. Patients were eliminated from the study if: (1) radical gastrectomy could not be completed; (2) end-to-side esophagojejunal anastomosis was not performed during the procedure; or (3) esophagojejunal anastomosis reinforcement was not possible. Double and a half layered esophagojejunal anastomosis was performed as follows: (1) Open surgery: the full thickness of the anastomosis is continuously sutured, followed by embedding the seromuscular layer with barbed or 3-0 absorbable sutures. The anastomosis is sutured with an average of six to eight stitches. (2) Laparoscopic surgery: the anastomosis is strengthened by counterclockwise full-layer sutures. Once the anastomosis has been sutured to the right posterior aspect of the anastomosis, the jejunum stump is pulled to the right and the anastomosis turned over to continue to complete reinforcement of the posterior wall. The suture interval is approximately 5 mm. After completing the full-thickness suture, the anastomosis is embedded in the seromuscular layer. Relevant data of patients who had undergone radical gastrectomy in the above 12 centers from June 2021 were collected and analyzed. The primary outcome was safety (e.g., postoperative complications, and treatment). Other studied variables included details of surgery (e.g., surgery time, intraoperative bleeding), postoperative recovery (postoperative time to passing flatus and oral intake, length of hospital stay), and follow-up conditions (quality of life as assessed by Visick scores). Result: [1] From June 2021 to September 2022,457 patients were enrolled, including 355 men and 102 women of median age 60.8±10.1 years and BMI 23.7±3.2 kg/m2. The tumors were located in the upper stomach in 294 patients, mid stomach in 139; and lower stomach in 24. The surgical procedures comprised 48 proximal gastrectomies and 409 total gastrectomies. Neoadjuvant chemotherapy was administered to 85 patients. Other organs were resected in 85 patients. The maximum tumor diameter was 4.3±2.2 cm, number of excised lymph nodes 28.3±15.2, and number of positive lymph nodes five (range one to four. As to pathological stage,83 patients had Stage I disease, 128 Stage II, 237 Stage III, and nine Stage IV. [2] The studied surgery-related variables were as follows: The operation was successfully completed in all patients, 352 via a transabdominal approach, 25 via a transhiatus approach, and 80 via a transthoracoabdominal approach. The whole procedure was performed laparoscopically in 53 patients (11.6%), 189 (41.4%) underwent laparoscopic-assisted surgery, and 215 (47.0%) underwent open surgery. The median intraoperative blood loss was 200 (range, 10-1 350) mL, and the operating time 215.6±66.7 minutes. The anastomotic reinforcement time was 2 (7.3±3.9) minutes for laparoscopic-assisted surgery, 17.6±1.7 minutes for total laparoscopy, and 6.0±1.2 minutes for open surgery. [3] The studied postoperative variables were as follows: The median time to postoperative passage of flatus was 3.1±1.1 days and the postoperative gastrointestinal angiography time 6 (range, 4-13) days. The median time to postoperative oral intake was 7 (range, 2-14) days, and the postoperative hospitalization time 15.8±6.7 days. [4] The safety-related variables were as follows: In total, there were 184 (40.3%) postoperative complications. These comprised esophagojejunal anastomosis complications in 10 patients (2.2%), four (0.9%) being anastomotic leakage (including two cases of subclinical leakage and two of clinical leakage; all resolved with conservative treatment); and six patients (1.3%) with anastomotic stenosis (two who underwent endoscopic balloon dilation 21 and 46 days after surgery, the others improved after a change in diet). There was no anastomotic bleeding. Non-anastomotic complications occurred in 174 patients (38.1%). All patients attended for follow-up at least once, the median follow-up time being 10 (3-18) months. Visick grades were as follows: Class I, 89.1% (407/457); Class II, 7.9% (36/457); Class III, 2.6% (12/457); and Class IV 0.4% (2/457). Conclusion: Double and a half layered esophagojejunal anastomosis in radical gastrectomy is safe and feasible.
Collapse
Affiliation(s)
- P F Ma
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - S Li
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - G Z Wang
- Department of General Surgery, Nanyang Central Hospital, Nanyang 473000,China
| | - X S Jing
- Department of General Surgery, Nanyang Central Hospital, Nanyang 473000,China
| | - D Y Liu
- Department of General Surgery, Zhumadian Central Hospital,Zhumadian 463000, China
| | - H Zheng
- Department of General Surgery, Zhumadian Central Hospital,Zhumadian 463000, China
| | - C H Li
- Department of General Surgery, Luoyang Central Hospital,Luoyang 471000, China
| | - Y S Wang
- Department of General Surgery, Luoyang Central Hospital,Luoyang 471000, China
| | - Y Z Wang
- Department of General Surgery, The First Affiliated Hospital of Henan Polytechnic University,Jiaozuo 454000, China
| | - Y Wu
- Department of General Surgery, The First Affiliated Hospital of Henan Polytechnic University,Jiaozuo 454000, China
| | - P Y Zhan
- Department of General Surgery, The First Affiliated Hospital of Henan University,Kaifeng 475000, China
| | - W F Duan
- Department of General Surgery, The First Affiliated Hospital of Henan University,Kaifeng 475000, China
| | - Q Q Liu
- Department of General Surgery, Luohe Central Hospital,Luohe 462000, China
| | - T Yang
- Department of General Surgery, Luohe Central Hospital,Luohe 462000, China
| | - Z M Liu
- Department of General Surgery, The People's Hospital of Hebi,Hebi 458000 China
| | - Q Y Jing
- Department of General Surgery, The People's Hospital of Hebi,Hebi 458000 China
| | - Z W Ding
- Department of General Surgery, First People's Hospital of Shangqiu,Shangqiu 476000, China
| | - G F Cui
- Department of General Surgery, First People's Hospital of Shangqiu,Shangqiu 476000, China
| | - Z Q Liu
- Department of General Surgery, Anyang Tumor Hospital,Anyang 455000, China
| | - G S Xia
- Department of General Surgery, Anyang Tumor Hospital,Anyang 455000, China
| | - G X Wang
- Department of General Surgery, First People's Hospital of Pingdingshan, Pingdingshan 467000, China
| | - P P Wang
- Department of General Surgery, First People's Hospital of Pingdingshan, Pingdingshan 467000, China
| | - L Gao
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
| | - D S Hu
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
| | - J L Zhang
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - Y H Cao
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - C Y Liu
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - Z Y Li
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - J C Zhang
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - C Z Li
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - Z Li
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| | - Y Z Zhao
- Department of General Surgery, Affiliated Tumor Hospital of Zhenzhou University(Henan Tumor Hospital), Zhengzhou 450003,China
| |
Collapse
|
16
|
Chen YN, Hu YX, Cao L, Zheng H, An ZJ. [Analysis on the vaccination coverage of 13-valent pneumococcal conjugate vaccine in China from 2017 to 2021]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1536-1541. [PMID: 37859368 DOI: 10.3760/cma.j.cn112150-20221222-01221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
Objective: To explore the vaccination coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China from 2017 to 2021. Methods: Using the reported number of PCV13 administrated doses from 2017 to 2021 and the population data from 31 provinces in China, which were collected by the Immunization Program Information System and summarized data at different levels (prefecture, provincial, and national). Collecting batch release data of PCV13 during the same period through the official website of the National Institutes for Food and Drug Control. The average coverage level of PCV13 was calculated by comparing the number of PCV13 vaccinations reported annually to the number of births in that year, and the spatial auto-correlation analysis was conducted in 2021 at the prefecture level. The coverage of PCV13 vaccination was estimated by the total vaccine doses administered each year divided by the number of newborn in the year, as of the administrated dose number per 100 people. Results: From March 2017 to December 2020, the total batch release of PCV13 was 20.06 million, with a total of 71.54, 384.75, 475.45, and 10.8886 million doses each year. During the same period, PCV13 reported doses were 20.2369 million and the vaccination doses from 2017 to 2021 were 4.08, 170.46, 407.52, 599.77, and 8.4185 million doses, respectively. From 2017 to 2021, the ratio of PCV13 doses administrated per 100 infants in each year was 0.25, 10.26, 23.81, 38.16, and 69.90 doses per 100 people, respectively. The range of the ratio in each province increased from 3.85 doses in 2017 to 264.41 doses per 100 people in 2021. The spatial auto-correlation analysis results showed that based on prefecture-level cities, there was spatial clustering in a certain area of PCV13 coverage from 2017 to 2021, and the spatial correlation in 2021 was the highest. The hotspot analysis showed that the hotspot areas with high coverage levels of PCV13 were concentrated in Jiangsu, Zhejiang, Shanghai, Fujian and their surrounding areas. The cold spots with low vaccine coverage were concentrated in Yunnan, Qinghai, Tibet, and their surrounding areas. Conclusion: The average coverage level of PCV13 is low in China with significant regional differences.
Collapse
Affiliation(s)
- Y N Chen
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Y X Hu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - L Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - H Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Z J An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
17
|
Soon YY, Zheng H, Tan TH, Lee SF, Leong YH, Wong LCC, Tey J, Ho F, Cheo T. Stroke Risk in Survivors of Head and Neck Cancer: A Descriptive Epidemiologic Cohort Study. Int J Radiat Oncol Biol Phys 2023; 117:e260-e261. [PMID: 37784998 DOI: 10.1016/j.ijrobp.2023.06.1214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Survivors of head and neck cancer (HNC) have an increased risk of stroke. However, the evidence on the risk of stroke in various subpopulations of HNC defined by patient, disease and treatment factors remains unclear. This study aimed to determine whether age-standardized incidence rate ratios (SIRs) and risk differences (SIRDs) of stroke varied across different subpopulations of survivors of HNC. MATERIALS/METHODS We used data from the national stroke and cancer registries to identify all cases of HNC who developed their first stroke after HNC diagnosis from January 2005 to December 2020. We estimated the SIRs and SIRDs of stroke in various subgroups of HNC defined by patient, disease and treatment factors using the Singapore general population as the reference group. RESULTS A total of 8839 cases of HNC were identified and 308 cases (3.4%) developed stroke after HNC diagnosis at median follow up of 42.5 months (interquartile range 15.0 - 94.5 months). The overall SIR and SIRD were 2.46 (95% CI 2.21 - 2.74) and 4.11 cases per 1000 person-years (PY) (95% CI 3.37 - 4.85). The SIR and SIRD were higher among those post five years from HNC diagnosis compared to those with 5 or fewer years from HNC diagnosis (SIR: 3.92 (3.36 - 4.58) vs 1.84 (1.59 - 2.14), SIRD: 6.64 (5.26 - 8.03) vs 2.65 (1.80 - 3.50) cases per 1000 PY). The SIR was highest for those less than 40 years old (< 40 years: 30.55; 40 - 49 years: 5.84; 50 - 59 years: 3.13; 60 - 69 years: 2.38, 70 - 79 years: 1.53, > = 80 years: 1.41) while SIRD was highest for those with age 80 years and above (< 40 years: 2.16; 40 - 49 years: 3.44, 50 - 59 years: 4.25, 60 - 69 years: 5.55, 70 - 79 years: 4.16, > = 80 years: 6.14). Among those who had treatment within 6 months of HNC diagnosis, the SIR and SIRD were significantly higher among those who had primary radiation treatment approach (radiation only, radiation and chemotherapy) (SIR: 3.01 (2.64 - 3.43), SIRD: 5.12 (4.18 - 6.29) cases per 1000 PY) compared to primary surgery treatment approach (surgery only, surgery and radiation, surgery and chemotherapy and radiation) (SIR: 1.64 (1.31 - 2.05), SIRD: 1.84 (0.92 - 3.67)). CONCLUSION The risk of stroke varied across different subpopulations of survivors of HNC with higher risk observed in those surviving five years post HNC diagnosis, less than 40 years old or received primary radiation treatment approach within 6 months from HNC diagnosis. A risk based prophylactic measures for stroke should be considered for different subpopulations of survivors of HNC.
Collapse
Affiliation(s)
- Y Y Soon
- National University Cancer Institute, Department of Radiation Oncology, Singapore, Singapore
| | - H Zheng
- National Registry of Diseases Office, Health Promotion Board, Singapore, Singapore
| | - T H Tan
- Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
| | - S F Lee
- National University Cancer Institute Singapore, Singapore, Singapore
| | - Y H Leong
- Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
| | - L C C Wong
- National University Cancer Institute Singapore, Singapore, Singapore
| | - J Tey
- National University Cancer Institute Singapore, Singapore, Singapore
| | - F Ho
- Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
| | - T Cheo
- National University Cancer Institute Singapore, Singapore, Singapore
| |
Collapse
|
18
|
Ng ZX, Handa P, Zheng H, Chen MZ, Soon YY, Ho F. Effects of Comprehensive Geriatric Assessment (CGA) Guided Care vs. Usual Care on Overall Survival (OS) and Health-Related Quality of Life (HRQL) for Older Adults with Cancer: A Systematic Review of Randomized Trials (RCTs). Int J Radiat Oncol Biol Phys 2023; 117:e609. [PMID: 37785831 DOI: 10.1016/j.ijrobp.2023.06.1980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There is evidence from RCTs demonstrating that our current models of CGA guided care can reduce treatment related toxicity effectively. However, it is unclear if CGA guided care can improve OS and HRQL. We aimed to determine the effect of CGA guided care compared with usual care on OS and HRQL. MATERIALS/METHODS We searched MEDLINE, EMBASE, CENTRAL and CINAHL from date of inception to October 2022 for RCTs comparing CGA guided care with usual care for patients with cancer who were 60 years old and greater on OS and HRQL. We assessed the risk of bias using Cochrane ROB 2 tool. We performed the meta-analysis using random-effects models. The I2 statistic was adopted to assess heterogeneity between studies. We adopted the Synthesis without meta-analysis approach for data not amenable for meta-analysis. The certainty of evidence was rated using the GRADE approach. This study is registered with Cochrane Database of Systematic Reviews. RESULTS We found 15 eligible RCTs including 3507 participants. There are variations in types of CGA used with 4 trials using CGA to recommend oncology treatment regimen and 10 trials making no recommendation on oncology treatment. The implementation of CGA recommendations were carried out by a geriatrician in 14 trials, but by the primary oncologist in 1 trial. Six, five and four RCTs were judged to have low, unclear and high risk of bias respectively. Eleven and six RCTs reported OS and HRQL outcomes respectively. There was no significant difference between CGA guided and usual care for OS (Hazard Ratio 1.02, 95% CI (0.90 to 1.15), I2 = 0%; moderate certainty). There was significant variation in the measurement of HRQL in terms of instruments, summary measures and time points. EORTC QLQ C30 and ELD 14 were used in 3 RCTs. The effects of CGA guided care on HRQL were inconsistent. Two trials using FACT-G or Elderly Functional Index (ELFI) reported significant improvement in HRQL at 3 and 6 months post randomization. Meta-analysis of the mean difference in the change of the EORTC QLQ C30 and E14 HRQL scores relative to baseline at 6 months post randomization demonstrated no significant difference between CGA guided and usual care for HRQL across various domains (moderate certainty evidence). CONCLUSION The current models of CGA guided care did not improve OS and had variable effects on HRQL when compared to usual care in older patients with cancer. The inconsistent effects of CGA guided care on HRQL suggest that CGA guided care may have more significant effects on the social and functional outcomes domains, aspects of HRQL that is predominantly measured in FACT-G and ELFI score respectively. There is also heterogeneity in how CGAs are performed and implemented. Future research should focus on developing new models of CGA guided care to improve OS and HRQL.
Collapse
Affiliation(s)
- Z X Ng
- National University Cancer Institute Singapore, Singapore, Singapore
| | - P Handa
- National University Cancer Institute Singapore, Singapore, Singapore
| | - H Zheng
- National Registry of Diseases Office, Health Promotion Board, Singapore, Singapore
| | - M Z Chen
- Division of Geriatric Medicine, Department of Medicine, National University Hospital, Singapore, Singapore
| | - Y Y Soon
- National University Cancer Institute, Department of Radiation Oncology, Singapore, Singapore
| | - F Ho
- Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore
| |
Collapse
|
19
|
Li Y, Phelan D, Ye F, Zheng H, Krivyakina E, Samarakoon A, LaBarre PG, Neu J, Siegrist T, Rosenkranz S, Syzranov SV, Ramirez AP. Evolution of magnetic surfboards and spin glass behavior in (Fe 1-pGa p) 2TiO 5. J Phys Condens Matter 2023; 35:475401. [PMID: 37557895 DOI: 10.1088/1361-648x/aceede] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 08/09/2023] [Indexed: 08/11/2023]
Abstract
The unusual anisotropy of the spin glass (SG) transition in the pseudobrookite system Fe2TiO5has been interpreted as arising from an induced, van der Waals-like, interaction among magnetic clusters. Here we present susceptibility (χ) and specific heat data (C) for Fe2TiO5diluted with non-magnetic Ga, (Fe1-pGap)2TiO5, for disorder parameterp= 0, 0.11, and 0.42, and elastic neutron scattering data forp= 0.20. A uniform suppression ofTgis observed upon increasingp, along with a value ofχTgthat increases asTgdecreases, i.e.dχ(Tg)/dTg<0We also observeCT∝T2in the low temperature limit. The observed behavior places (Fe1-pGap)2TiO5in the category of a strongly geometrically frustrated SG.
Collapse
Affiliation(s)
- Y Li
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
| | - D Phelan
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
| | - F Ye
- Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37830, United States of America
| | - H Zheng
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
| | - E Krivyakina
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
- Department of Physics, Northern Illinois University, DeKalb, IL 60115, United States of America
| | - A Samarakoon
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
| | - P G LaBarre
- Physics Department, University of California Santa Cruz, Santa Cruz, CA 95064, United States of America
| | - J Neu
- National High Magnetic Field Laboratory, Tallahassee, FL 32310, United States of America
- Nuclear Nonproliferation Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, United States of America
| | - T Siegrist
- National High Magnetic Field Laboratory, Tallahassee, FL 32310, United States of America
- Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Tallahassee, FL 32310, United States of America
| | - S Rosenkranz
- Materials Science Division, Argonne National Laboratory, Lemont, IL 60439, United States of America
| | - S V Syzranov
- Physics Department, University of California Santa Cruz, Santa Cruz, CA 95064, United States of America
| | - A P Ramirez
- Physics Department, University of California Santa Cruz, Santa Cruz, CA 95064, United States of America
| |
Collapse
|
20
|
Zeng YL, Wang SD, Li YR, Xue WS, Wang T, Tang YT, Zheng H, Chen ZX, Lan JQ, Yan J. [Analysis of factors influencing the success rate of organoid culture in 1231 cases of colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 2023; 26:780-786. [PMID: 37574295 DOI: 10.3760/cma.j.cn441530-20221128-00499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
Objective: To investigate the risk factors for organoid culture failure in colorectal cancer. Methods: This was a retrospective observational study. Tumor specimens were obtained from 1130 patients with colorectal cancer who had undergone surgery or biopsy and had no other concurrent malignancies at Nanfang Hospital of Southern Medical University from December 2021 to November 2022. Organoid culture was performed on 1231 tumor tissue samples. Univariate analysis and multivariate logistic regression were used to analyze the factors that might have influenced the rate of successful organoid culture of colorectal cancer tissue samples. Results: The median (range) duration of organoid culture was 7 (3-12) days. The overall rate of successful culture was 76.3% (939/1231). The rate of successful organoid cultures varied according to the sampling site, malignant ascites having the highest success rate (96.4%, 27/28), followed by liver metastases (83.1%, 54/65), lung metastases (8/10), primary tumors (76.0%, 816/1074), omental metastases (10/14), peritoneal metastases (61.5%, 16/26), ovarian metastases (3/5), and lymph node metastases (5/9). The difference in rates of successful organoid culture between primary tumors and malignant ascites was statistically significant (P=0.012), whereas none of the other rates of successful organoid culture success differed significantly (all P>0.05). The rate of successful organoid culture was 96.4% (27/28) for malignant ascites obtained by abdominal puncture, 76.5% (864/1130) for surgical specimens, and 65.8% (48/73) for endoscopic biopsies; these differences are statistically significant (χ2=10.773, P=0.005). The rate of successful organoid culture was 62.5% (40/64) in the neoadjuvant chemoradiotherapy group, which is significantly lower than in the non-adjuvant (76.9%, 787/1023) and chemotherapy groups (77.8%, 112/144) (χ2=7.134, P=0.028). Multivariate logistic regression analysis revealed that endoscopic biopsy (OR=0.557, 95%CI: 0.335-0.924, P=0.024) and neoadjuvant chemoradiotherapy (OR=0.483, 95%CI: 0.285-0.820, P=0.007) were independent risk factors for failure of organoid culture of colorectal cancer samples. Malignant ascites (OR=8.537, 95%CI:1.154-63.131,P=0.036) and abdominal puncture (OR=8.294, 95% CI: 1.112-61.882, P=0.039) were identified as independent protective factors. Conclusions: The rate of successful organoid culture was influenced by the sampling site, sampling method, and chemoradiotherapy. The rate of successful organoid culture was lower for endoscopic biopsies and in patients receiving preoperative neoadjuvant chemoradiotherapy, and higher for malignant ascites. We consider that culture of malignant ascites is preferable when peritoneal metastases are suspected.
Collapse
Affiliation(s)
- Y L Zeng
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - S D Wang
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Y R Li
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - W S Xue
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - T Wang
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Y T Tang
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - H Zheng
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Z X Chen
- Guangdong Research Center of Organoid Engineering and Technology, Guangzhou 510535, China
| | - J Q Lan
- Guangdong Research Center of Organoid Engineering and Technology, Guangzhou 510535, China
| | - J Yan
- Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China Department of Gastrointestinal Surgery, Shenzhen People' s Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518020, China
| |
Collapse
|
21
|
Xu XC, Zheng H. [Wu Shou and his work Shang Han Yun Yao Quan Shu published in the Ming Dynasty]. Zhonghua Yi Shi Za Zhi 2023; 53:141-146. [PMID: 37474330 DOI: 10.3760/cma.j.cn112155-20211001-00113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Abstract
Wu Shou was a doctor in a medical family in Qiantang, Zhejiang in the Ming Dynasty. He was promoted as a medical officer in the local government and the Imperial Academy of Medicine. His work, considered a masterpiece Shang Han Yun Yao Quan Shu was published around 1505. The series consisted of four volumes. The main content of the book focused on the taxonomy study to the Treatise on Febrile Diseases (Shang Han Lun). Wu Shou was politically accused of being a person who pursued fame and fortune but lacked medical skills because of the conflicts and contradiction between medical officials and the political service system in the period of the Chenghua and Hongzhi in the Ming Dynasty. However, his medical and academic thinking and skills for typhoid treatment shown in the book demonstrated that they were not as awful as what was described at that time.
Collapse
|
22
|
Guo XQ, Zhang S, Zheng H, Wang F, Miao N, Su QD, Bi SL, Zhang GM, Wang FZ, Shen LP. [Epidemiological distribution of genotypes and sub-genotypes of hepatitis B virus in 15 ethnic groups in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:759-764. [PMID: 37221064 DOI: 10.3760/cma.j.cn112338-20221130-01021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Objective: To understand the distribution of genotypes and sub-genotypes of HBV in different ethnic groups in China. Methods: The HBsAg positive samples were selected by stratified multi-stage cluster sampling from the sample base of national HBV sero-epidemiological survey in 2020 for the amplification of S gene of HBV by nested PCR. A phylogeny tree was constructed to determine the genotypes and sub-genotypes of HBV. The distribution of genotypes and sub-genotypes of HBV were analyzed comprehensively by using laboratory data and demographic data. Results: A total of 1 539 positive samples from 15 ethnic groups were successfully amplified and analyzed, and 5 genotypes (B, C, D, I and C/D) were detected. The proportion of genotype B was higher in ethnic group of Han (74.52%, 623/836), Zhuang (49.28%, 34/69), Yi (53.19%, 25/47), Miao (94.12%, 32/34), Buyi (81.48%, 22/27). The proportions of genotype C were higher in ethnic groups of Yao (70.91%, 39/55). Genotype D was the predominant genotype in Uygur (83.78%, 31/37). Genotype C/D were detected in Tibetan (92.35%,326/353). In this study, 11 cases of genotype I were detected, 8 of which were distributed in Zhuang nationality. Except for Tibetan, sub-genotype B2 accounted for more than 80.00% in genotype B in all ethnic groups. The proportions of sub-genotype C2 were higher in 8 ethnic groups, i.e. Han, Tibetan, Yi, Uygur, Mongolian, Manchu, Hui and Miao. The proportions of sub-genotype C5 were higher in ethnic groups of Zhuang (55.56%, 15/27) and Yao (84.62%, 33/39). For genotype D, sub-genotype D3 was detected in Yi ethnic group and sub-genotype D1 was detected in both Uygur and Kazak. The proportions of sub-genotype C/D1 and C/D2 in Tibetan were 43.06% (152/353) and 49.29% (174/353). For all the 11 cases of genotype I infection, only sub-genotype I1 was detected. Conclusions: Five genotypes and 15 sub-genotypes of HBV were found in 15 ethnic groups. There were significant differences in the distribution of genotypes and sub-genotypes of HBV among different ethnic groups.
Collapse
Affiliation(s)
- X Q Guo
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - S Zhang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - H Zheng
- Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - F Wang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - N Miao
- Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Q D Su
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - S L Bi
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - G M Zhang
- Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - F Z Wang
- Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - L P Shen
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|
23
|
Zheng H, Zhang JW, Zhang T, Liu YG, Jiang ST, Zhang YS, Zhang L, Xu YY, Zhao HT, Lu X, Sang XT. [Application of augmented reality navigation in laparoscopic and robot-assisted liver surgery]. Zhonghua Wai Ke Za Zhi 2023; 61:431-436. [PMID: 36987677 DOI: 10.3760/cma.j.cn112139-20221012-00435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/30/2023]
Abstract
In recent years, laparoscopic surgery and robotic surgery have been widely used, and various intraoperative image navigation systems have also developed rapidly. However, the liver itself has a complex vessel and duct system, which increase the difficulty of liver surgery. The augmented reality image navigation system combines the three-dimensional reconstructed image of the liver with the real liver anatomy, which presents the specific relationship between the tumor location and the surrounding vessels for the surgeon. Compared with other intraoperative image navigation methods, augmented reality has its unique advantages. This paper provides an overview of current advances in registration technology in augmented reality image navigation system, and focuses on its applications in liver surgery, including laparoscopic surgery and robotic surgery. Finally, the technological problems and difficulties still faced at present are summarized, and future directions worth studying in this field are proposed.
Collapse
Affiliation(s)
- H Zheng
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - J W Zhang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - T Zhang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Y G Liu
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - S T Jiang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Y S Zhang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - L Zhang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - Y Y Xu
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - H T Zhao
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - X Lu
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| | - X T Sang
- Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, Beijing 100730, China
| |
Collapse
|
24
|
Qi YQ, Zheng H. [The sources and spread of Zhong Jing Quan Shu related to Zhang Qingzi]. Zhonghua Yi Shi Za Zhi 2023; 53:100-106. [PMID: 37183624 DOI: 10.3760/cma.j.cn112155-20220328-00034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
The original version and title of Zhong Jing Quan Shu referred to the collection of four books - Shang Han Lun, Zhu Jie Shang Han Lun, Shang Han Lei Zheng and Jin Gui Yao Lue Fang Lun, published by Zhao Kaimei in the Ming Dynasty. Then, Zhang Qingzi Shang Han Lun was written by Zhang Qingzi. After that, a Japanese scholar compiled a new collection based on Zhong Jing Quan Shu held in the Cabinet Library in Japan consisting of three books - Shang Han Lei Zheng, JinGui Yao Lue Fang Lun and Zhang Qingzi Shang Han Lun. The preface and content in this collection was adjusted for some practical purposes and was published in the second year of Manji in Japan (1659). This book, Zhang Qingzi Shang Han Lun was based on Shang Han Lun from the early and mid-Edo period of Japan. It was then returned to China in the Guangxu period of the Qing Dynasty. It was soon republished by Deng in Chengdu, with Yun Qi Zhang Jue Lu and Shang Han Ming Li Lun, added as a collection of five books with the same name Zhang Zi Qing Shang Han Lun, being popular in the late Qing Dynasty and the Republic of China. This book was understood to be from Zhong Jing Quan Shu published by Zhao Kaimei during this period. These two books were distinguished from each other when Shang Han Lun published in the Song Dynasty, drew people's attention. However, Zhang Qingzi Shang Han Lun was still believed valuable for both clinical and literature studies.
Collapse
Affiliation(s)
- Y Q Qi
- School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - H Zheng
- School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
| |
Collapse
|
25
|
Zheng H, Wang Q, Fu T, Wei Z, Ye J, Huang B, Li C, Liu B, Zhang A, Li F, Gao F, Tong W. Robotic versus laparoscopic left colectomy with complete mesocolic excision for left-sided colon cancer: a multicentre study with propensity score matching analysis. Tech Coloproctol 2023:10.1007/s10151-023-02781-7. [PMID: 36964884 DOI: 10.1007/s10151-023-02781-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 02/28/2023] [Indexed: 03/26/2023]
Abstract
BACKGROUND Robotic surgery for right-sided colon and rectal cancer has rapidly increased; however, there is limited evidence in the literature of advantages of robotic left colectomy (RLC) for left-sided colon cancer. The purpose of this study was to compare the outcomes of RLC versus laparoscopic left colectomy (LLC) with complete mesocolic excision (CME) for left-sided colon cancer. METHODS Patients who had RLC or LLC with CME for left-sided colon cancer at 5 hospitals in China between January 2014 and April 2022 were included. A one-to-one propensity score matched analysis was performed to decrease confounding. The primary outcome was postoperative complications occurring within 30 days of surgery. Secondary outcomes were disease-free survival, overall survival and the number of harvested lymph nodes. RESULTS A total of 292 patients (187 males; median age 61.0 [20.0-85.0] years) were eligible for this study, and propensity score matching yielded 102 patients in each group. The clinical-pathological characteristics were well-matched between groups. The two groups did not differ in estimated blood loss, conversion to open rate, time to first flatus, reoperation rate, or postoperative length of hospital stay (p > 0.05). RLC was associated with a longer operation time (192.9 ± 53.2 vs. 168.9 ± 52.8 minutes, p=0.001). The incidence of postoperative complications did not differ between the RLC and LLC groups (18.6% vs. 17.6%, p = 0.856). The total number of lymph nodes harvested in the RLC group was higher than that in the LLC group (15.7 ± 8.3 vs. 12.1 ± 5.9, p< 0.001). There were no significant differences in 3-year and 5-year overall survival or 3-year and 5-year disease-free survival. CONCLUSIONS Compared to laparoscopic surgery, RLC with CME for left-sided colon cancer was found to be associated with higher numbers of lymph nodes harvested and similar postoperative complications and long-term survival outcomes.
Collapse
Affiliation(s)
- H Zheng
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China
| | - Q Wang
- Department of Gastrocolorectal Surgery, The First Hospital of Jilin University, Changchun, China
| | - T Fu
- Department of Gastrointestinal Surgery II, Renmin Hospital of Wuhan University, Wuhan, China
| | - Z Wei
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - J Ye
- Department of Gastrointestinal Surgery, The People's Hospital of Shapingba District, Chongqing, China
| | - B Huang
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China
| | - C Li
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China
| | - B Liu
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China
| | - A Zhang
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China
| | - F Li
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China.
| | - F Gao
- Department of Colorectal Surgery, 940th Hospital of Joint Logistics Support force of PLA, Lanzhou, China.
| | - W Tong
- Gastric and Colorectal Surgery Division, Department of General Surgery, Army Medical Center (Daping Hospital), Army Medical University, No. 10, Changjiang Branch Road, Daping, Yuzhong District, Chongqing, China.
| |
Collapse
|
26
|
Zhang L, Wang J, Cui H, Zheng H, Yin X, Lin J, Wang Y, Zhao Y, Li H, Chen Q. Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine. ACS Appl Mater Interfaces 2023; 15:12864-12881. [PMID: 36856003 DOI: 10.1021/acsami.3c00986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Tumors managing to exempt from immune clearance are attributable to their overexpressed immune suppressive molecules (CD47, PD-L1, etc.). Leadingly, the checkpoint blockade-based chemoimmunotherapy by means of knockdown of these immunosuppressive checkpoints, together with immunogenetic chemotherapeutics, is perceived to be a valid therapeutic strategy for improving anti-tumor outcomes. Herein, chemotherapeutic camptothecin was covalently introduced into an intriguing multifaceted nanomedicine. Note that the elaborated nanomedicine was chemically engineered to enable targeted transportation to the tumors via systemic administration, possessing intelligent responsiveness to sequential extracellular and intracellular microenvironments in the targeted tumors for prompted transcellular endocytosis owing to enzymolysis by the tumor-enriched matrix metalloproteinases and the selective liberation of cytocidal camptothecin in the cell interiors owing to thiolysis by glutathione. In addition, this chemotherapeutic nanomedicine allowed facile encapsulation of the negatively charged RNA interference payloads. Consequently, aiming for treatment of intractable triple-negative breast tumors, we attempted the small interfering RNA (siRNA) payloads aiming for CD47 and PD-L1 into the aforementioned nanomedicine. The subsequent investigations demonstrated drastic knockdown of these vital immune suppressive checkpoints by this siRNA-encapsulating chemotherapeutic nanomedicine, conducing to the reversal of the immune checkpoint suppressive microenvironment of triple-negative 4T1 tumors. Namely, the inhibited proceedings of the innate and adaptive anti-tumor immunities were revived, as supported by observation of the activated infiltration and retention of CD68+ macrophages and CD4+ and CD8+ lymphocytes into the tumors. Eventually, most potent anti-tumor efficacies were accomplished by systemic administration of this chemoimmunotherapeutic nanomedicine, which verified the amplified contribution from anti-tumor immunities by means of knockdown of the immune suppressive molecules to the ultimate anti-tumor efficacies. Note that the upregulation of the immune suppressive molecules was constantly reported in a variety of clinical therapies; hence, our facile chemoimmunotherapeutic platform should be emphasized in clinical translation for seeking improved therapeutic outcomes.
Collapse
Affiliation(s)
- Liuwei Zhang
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Jingyun Wang
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Hongyan Cui
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Haonan Zheng
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Xiaolan Yin
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Jiaqi Lin
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Yue Wang
- Department of Gastric Cancer, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning 110042, China
- Provincial Key Laboratory of Interdisciplinary Medical Engineering for Gastrointestinal Carcinoma, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning 110042, China
| | - Yan Zhao
- Department of Gastric Cancer, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning 110042, China
- Provincial Key Laboratory of Interdisciplinary Medical Engineering for Gastrointestinal Carcinoma, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning 110042, China
| | - Haidong Li
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
| | - Qixian Chen
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
- School of Bioengineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China
- Provincial Key Laboratory of Interdisciplinary Medical Engineering for Gastrointestinal Carcinoma, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Liaoning 110042, China
| |
Collapse
|
27
|
Li Y, Huang J, Bao L, Zhu J, Duan W, Zheng H, Wang H, Jiang Y, Liu W, Zhang M, Yu Y, Yi C, Ji X. RNA Pol II preferentially regulates ribosomal protein expression by trapping disassociated subunits. Mol Cell 2023; 83:1280-1297.e11. [PMID: 36924766 DOI: 10.1016/j.molcel.2023.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 12/12/2022] [Accepted: 02/23/2023] [Indexed: 03/17/2023]
Abstract
RNA polymerase II (RNA Pol II) has been recognized as a passively regulated multi-subunit holoenzyme. However, the extent to which RNA Pol II subunits might be important beyond the RNA Pol II complex remains unclear. Here, fractions containing disassociated RPB3 (dRPB3) were identified by size exclusion chromatography in various cells. Through a unique strategy, i.e., "specific degradation of disassociated subunits (SDDS)," we demonstrated that dRPB3 functions as a regulatory component of RNA Pol II to enable the preferential control of 3' end processing of ribosomal protein genes directly through its N-terminal domain. Machine learning analysis of large-scale genomic features revealed that the little elongation complex (LEC) helps to specialize the functions of dRPB3. Mechanistically, dRPB3 facilitates CBC-PCF11 axis activity to increase the efficiency of 3' end processing. Furthermore, RPB3 is dynamically regulated during development and diseases. These findings suggest that RNA Pol II gains specific regulatory functions by trapping disassociated subunits in mammalian cells.
Collapse
Affiliation(s)
- Yuanjun Li
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Jie Huang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Lijun Bao
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Junyi Zhu
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Wenjia Duan
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Haonan Zheng
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Hui Wang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Yongpeng Jiang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Weiwei Liu
- Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
| | - Meiling Zhang
- State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Department of Chemical Biology and Synthetic and Functional Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - Yang Yu
- Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
| | - Chengqi Yi
- State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Department of Chemical Biology and Synthetic and Functional Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - Xiong Ji
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
| |
Collapse
|
28
|
Zhang M, Wu D, Li YX, Zheng H, Yin ZD, Liang XF. [Challenges to global pertussis prevention and control]. Zhonghua Liu Xing Bing Xue Za Zhi 2023; 44:491-497. [PMID: 36942347 DOI: 10.3760/cma.j.cn112338-20220825-00737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
Pertussis is an acute, highly infectious respiratory disease caused by Bordetella pertussis, and is one of the leading causes of infant disease and death worldwide. The pertussis vaccine has been used in the expanded program on immunization globally since 1974 and the vaccination coverage remains high. In recent years, the pertussis incidence rate increased, even pertussis outbreaks occurred, in more and more countries or areas after years with low incidence level. The disease burden of pertussis has been seriously underestimated, and the prevention and control of pertussis is facing many challenges. This article reviews the epidemic status of pertussis worldwide, the factors affecting the reemergence of pertussis, and the challenges in the prevention and control to provide a reference for prevention and control of pertussis.
Collapse
Affiliation(s)
- M Zhang
- School of Public Health, Shanxi Medical University, Taiyuan 030001, China
| | - D Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Y X Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - H Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Z D Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - X F Liang
- Kangtai Biological Vaccine Industry Research Institute/Disease Prevention and Control Institute of Jinan University, Guangzhou 510632, China
| |
Collapse
|
29
|
Cheng W, Zhou Y, Chu X, Huang S, Zheng X, Zheng H. Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis. Actas Urol Esp 2023; 47:92-98. [PMID: 36586485 DOI: 10.1016/j.acuroe.2022.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 03/06/2022] [Indexed: 12/29/2022]
Abstract
INTRODUCTION We performed a meta-analysis to evaluate the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. METHODS A systematic literature search up to November 2021 was done and 6 studies included 389 subjects with non-muscle invasive bladder cancer at the start of the study; 197 of them were provided with intravesical-mitomycin and 192 with intravesical gemcitabine. The studies reported the relationships about the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) to assess the effect of intravesical mitomycin compared with gemcitabine on the treatment of non-muscle invasive bladder cancer using the dichotomous method with a random or fixed-effect model. RESULTS Intravesical mitomycin had significantly higher recurrence rates (OR, 2.41; 95% CI, 1.43-4.08, p=0.001) and chemical cystitis (OR, 4.39; 95% CI, 2.27-8.51, p<0.001) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. However, intravesical mitomycin had no significant difference in its effect on hematuria (OR, 1.71; 95% CI, 0.68-4.33, p=0.26), skin reaction (OR, 2.04; 95% CI, 0.59-7.07, p=0.26), and liver and kidney functions damage (OR, 1.96; 95% CI, 0.35-10.96, p=0.44) compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. CONCLUSIONS Intravesical mitomycin had significantly higher recurrence rates and chemical cystitis and no significant difference in its effect on hematuria, skin reaction, and liver and kidney functions damage compared to intravesical gemcitabine in subjects with non-muscle invasive bladder cancer. Further studies are required to validate these findings.
Collapse
Affiliation(s)
- W Cheng
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China
| | - Y Zhou
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China
| | - X Chu
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China
| | - S Huang
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China
| | - X Zheng
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China.
| | - H Zheng
- Department of Urology, The Fifth Affiliated Hospital of Sun Yet-sun University, Zhuhai, Guangdong, China
| |
Collapse
|
30
|
Liu Y, Wang K, Zheng H, Ma M, Li S, Ma L. Papain immobilization on interconnected-porous chitosan macroparticles: Application in controllable hydrolysis of egg white for foamability improvement. Food Hydrocoll 2023. [DOI: 10.1016/j.foodhyd.2023.108551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
31
|
Ho JSY, Sia CH, Zheng H, Tan BYQ, Ho AFW, Yeo LLL, Chan MYY. Interplay between post-myocardial infarction ejection fraction and atrial fibrillation: implications for ischemic stroke. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Singapore Ministry of Health’s National Medical Research Council
Background
There are little data on the interplay between post-acute myocardial infarction (MI), left ventricular systolic dysfunction and atrial fibrillation (AF) and the impact on subsequent acute ischemic stroke (AIS), particularly among patients with moderately reduced ejection fraction (EF).
Purpose
We aimed to study the association between low EF, AF and the risk and severity of AIS.
Methods
This study linked national, population-based data from the Singapore Myocardial Infarction Registry with the Singapore Stroke Registry from 2007 to 2018. The EF and AF status were recorded during the index MI hospitalization. Patients were grouped based on an EF of ≥50% or <50%. An additional grouping of patients with AMI in 2008 to 2018 and EF of ≥50% (normal EF), 40-49% (mildly reduced EF) or <40% (reduced EF) was done. The primary outcome of interest was the risk of developing an AIS after an AMI. The secondary outcome of interest was the National Institute of Health Stroke Scale (NIHSS) across the different strata of EF among AMI patients with subsequent AIS.
Results
There were 64512 patients available for analysis. The median age was 65.7 and 69.5% were male. The median duration from MI to AIS was 16.9 (IQR 1.6-46.1) months. Low EF <40% was independently associated with subsequent AIS (adjusted HR 1.18, 95% CI 1.10-1.27), as was EF 40-49% (adjusted HR 1.16, 95% CI 1.06-1.27). Among patients with AF, EF<50% was not a statistically significant predictor of AIS (adjusted HR 1.08, 95% CI 0.96-1.23). In patients without AF, the mildly reduced EF group had an increased aHR of AIS of 1.18 (95% CI 1.06-1.31), but not those with AF (aHR 1.03, 95% CI 0.87-1.23). The cubic spline curves of continuous EF against relative hazard for stroke stratified by presence of AF is shown in Figure 1. Patients with low EF without AF had highest median NIHSS score during subsequent AIS (EF <40% NIHSS 6-9; EF 40-49% NIHSS 4; EF ≥50% NIHSS 4).
Conclusions
Reduced and moderately reduced EF post-MI was independently associated with subsequent AIS and was associated with increased AIS severity in patients without AF but not in those with AF. Further research is needed to mitigate the risk of late AIS among post-MI patients with reduced EF along with AF.
Collapse
Affiliation(s)
- J S Y Ho
- National University Heart Centre , Singapore , Singapore
| | - C H Sia
- National University Heart Centre , Singapore , Singapore
| | - H Zheng
- Health Promotion Board , Singapore , Singapore
| | - B Y Q Tan
- National University Hospital, Division of Neurosurgery, Department of Surgery , Singapore , Singapore
| | - A F W Ho
- Singapore General Hospital, Department of Emergency Medicine , Singapore , Singapore
| | - L L L Yeo
- National University Hospital, Division of Neurosurgery, Department of Surgery , Singapore , Singapore
| | - M Y Y Chan
- National University Heart Centre , Singapore , Singapore
| |
Collapse
|
32
|
Zoumplis A, Kolody B, Kaul D, Zheng H, Venepally P, McKnight DM, Takacs-Vesbach C, DeVries A, Allen AE. Impact of meltwater flow intensity on the spatiotemporal heterogeneity of microbial mats in the McMurdo Dry Valleys, Antarctica. ISME Commun 2023; 3:3. [PMID: 36690784 PMCID: PMC9870883 DOI: 10.1038/s43705-022-00202-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 11/13/2022] [Accepted: 11/16/2022] [Indexed: 01/24/2023]
Abstract
The meltwater streams of the McMurdo Dry Valleys are hot spots of biological diversity in the climate-sensitive polar desert landscape. Microbial mats, largely comprised of cyanobacteria, dominate the streams which flow for a brief window of time (~10 weeks) over the austral summer. These communities, critical to nutrient and carbon cycling, display previously uncharacterized patterns of rapid destabilization and recovery upon exposure to variable and physiologically detrimental conditions. Here, we characterize changes in biodiversity, transcriptional responses and activity of microbial mats in response to hydrological disturbance over spatiotemporal gradients. While diverse metabolic strategies persist between marginal mats and main channel mats, data collected from 4 time points during the austral summer revealed a homogenization of the mat communities during the mid-season peak meltwater flow, directly influencing the biogeochemical roles of this stream ecosystem. Gene expression pattern analyses identified strong functional sensitivities of nitrogen-fixing marginal mats to changes in hydrological activities. Stress response markers detailed the environmental challenges of each microhabitat and the molecular mechanisms underpinning survival in a polar desert ecosystem at the forefront of climate change. At mid and end points in the flow cycle, mobile genetic elements were upregulated across all mat types indicating high degrees of genome evolvability and transcriptional synchronies. Additionally, we identified novel antifreeze activity in the stream microbial mats indicating the presence of ice-binding proteins (IBPs). Cumulatively, these data provide a new view of active intra-stream diversity, biotic interactions and alterations in ecosystem function over a high-flow hydrological regime.
Collapse
Affiliation(s)
- A Zoumplis
- Scripps Institution of Oceanography, University of California, San Diego, CA, USA
- Microbial and Environmental Genomics Group, J. Craig Venter Institute, La Jolla, CA, USA
| | - B Kolody
- Earth and Planetary Science, University of California, Berkeley, Berkeley, CA, USA
| | - D Kaul
- Microbial and Environmental Genomics Group, J. Craig Venter Institute, La Jolla, CA, USA
| | - H Zheng
- Microbial and Environmental Genomics Group, J. Craig Venter Institute, La Jolla, CA, USA
| | - P Venepally
- Microbial and Environmental Genomics Group, J. Craig Venter Institute, La Jolla, CA, USA
| | - D M McKnight
- Institute of Arctic and Alpine Research, University of Colorado, Boulder, CO, USA
| | - C Takacs-Vesbach
- Department of Biology, University of New Mexico, Albuquerque, NM, USA
| | - A DeVries
- Evolution, Ecology and Behavior, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - A E Allen
- Scripps Institution of Oceanography, University of California, San Diego, CA, USA.
- Microbial and Environmental Genomics Group, J. Craig Venter Institute, La Jolla, CA, USA.
| |
Collapse
|
33
|
Xu H, Zheng H, Zhang Q, Song H, Wang Q, Xiao J, Dong Y, Shen Z, Wang S, Wu S, Wei Y, Lu W, Zhu Y, Niu X. A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts. Clin Oncol (R Coll Radiol) 2023; 35:e48-e59. [PMID: 35781406 DOI: 10.1016/j.clon.2022.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 04/21/2022] [Accepted: 06/09/2022] [Indexed: 01/04/2023]
Abstract
AIMS Medication for advanced sarcomas has not improved for three decades. Patient-derived tumour xenografts (PDTX) are a promising solution for developing new therapies and real-time personalised medicine because of their highly effective prediction of drug efficacy. However, there is a dearth of PDTX models for sarcomas due to the scarcity and heterogeneity of the disease. MATERIALS AND METHODS A multicentre clinical collaborative study (ChiCTR-OOC-17013617) was carried out. Fresh patient tumour tissues via resection or biopsy were used for the PDTX set-up. The standard medical care chosen by the physician was given to the patient, in parallel with testing on multiple regimens. The outcomes of patients' responses and PDTX tests were compared. Comprehensive analyses were carried out to assess the clinical value of PDTX for the treatment of sarcomas. Living tissues from successfully engrafted cases were deposited into a repository. RESULTS Forty-two cases, including 36 bone sarcomas and six soft-tissue sarcomas, were enrolled; the overall engraftment rate was 73.8%. Histopathological examination showed a 100% consistency between primary tumours and tumour grafts. The engraftment rate was independent of age, gender and sampling methods, but was associated with subtypes of tumour. The outgrowth time of tumour grafts could be associated with prognosis. Major somatic mutations in tumour grafts occurred primarily in common tumour driver genes. Poor prognosis was associated with the KMT2C mutation. A drug efficacy test showed complete concordance between the PDTX model and patients' responses in 17 regimens. CONCLUSION PDTX is an ideal preclinical model for sarcomas because of its faithful preservation of the heterogeneity of the disease, a satisfactory engraftment rate and high accuracy in its prediction of drug efficacy.
Collapse
Affiliation(s)
- H Xu
- Beijing Jishuitan Hospital, Beijing, China
| | - H Zheng
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - Q Zhang
- Beijing Jishuitan Hospital, Beijing, China
| | - H Song
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - Q Wang
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - J Xiao
- Changzheng Hospital, Shanghai, China
| | - Y Dong
- The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Z Shen
- The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - S Wang
- Spine Surgery, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - S Wu
- Jinling Hospital, Nanjing, Jiangsu, China
| | - Y Wei
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - W Lu
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Y Zhu
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - X Niu
- Beijing Jishuitan Hospital, Beijing, China.
| |
Collapse
|
34
|
Liu W, Liu J, Liu X, Zheng H, Liu J. Bioinspired Hydrophobic Single-Atom Catalyst with Flexible Sulfur Motif for Aqueous-Phase Hydrogenative Transformation. ACS Catal 2022. [DOI: 10.1021/acscatal.2c05862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Wengang Liu
- College of Material Science and Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China
- Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Shandong Energy Institute, Qingdao 266101, P. R. China
| | - Jiachang Liu
- College of Material Science and Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China
| | - Xilu Liu
- College of Material Science and Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China
| | - Haonan Zheng
- College of Material Science and Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China
| | - Jian Liu
- College of Material Science and Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China
- Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Shandong Energy Institute, Qingdao 266101, P. R. China
| |
Collapse
|
35
|
Zhang J, Hussein M, Kao SH, Clay T, Singhal N, Kim H, Cho E, Shim B, Lee Y, Lee GW, Zhao J, Yu Y, Sun M, Lin CB, Yang TY, Chang GC, Zheng H, Tan W, Spigel D. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
36
|
Frentzas S, Meniawy T, Kao SH, Coward J, Clay T, Singhal N, Black A, Xu W, Kumar R, Lee Y, Lee GW, Liao W, Zhong D, Shiah HS, Chen YM, Gao R, Wang R, Zheng H, Tan W, Cho E. 126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
37
|
Lin X, Zhou X, Tong T, Nie X, Wang L, Zheng H, Li J, Xue E, Chen S, Zheng M, Chen C, Jiang H, Du M, Gao Q. A Super-resolution Guided Network for Improving Automated Thyroid Nodule Segmentation. Comput Methods Programs Biomed 2022; 227:107186. [PMID: 36334526 DOI: 10.1016/j.cmpb.2022.107186] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 10/03/2022] [Accepted: 10/15/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND AND OBJECTIVE A thyroid nodule is an abnormal lump that grows in the thyroid gland, which is the early symptom of thyroid cancer. In order to diagnose and treat thyroid cancer at the earliest stage, it is desired to characterize the nodule accurately. Ultrasound thyroid nodules segmentation is a challenging task due to the speckle noise, intensity heterogeneity, low contrast and low resolution. In this paper, we propose a novel framework to improve the accuracy of thyroid nodules segmentation. METHODS Different from previous work, a super-resolution reconstruction network is firstly constructed to upscale the resolution of the input ultrasound image. After that, our proposed N-shape network is utilized to perform the segmentation task. The guidance of super-resolution reconstruction network can make the high-frequency information of the input thyroid ultrasound image richer and more comprehensive than the original image. Our N-shape network consists of several atrous spatial pyramid pooling blocks, a multi-scale input layer, a U-shape convolutional network with attention blocks and a proposed parallel atrous convolution(PAC) module. These modules are conducive to capture context information at multiple scales so that semantic features can be fully utilized for lesion segmentation. Especially, our proposed PAC module is beneficial to further improve the segmentation by extracting high-level semantic features from different receptive fields. We use the UTNI-2021 dataset for model training, validating and testing. RESULTS The experimental results show that our proposed method achieve a Dice value of 91.9%, a mIoU value of 87.0%, a Precision value of 88.0%, a Recall value 83.7% and a F1-score value of 84.3%, which outperforms most state-of-the-art methods. CONCLUSIONS Our method achieves the best performance on the UTNI-2021 dataset and provides a new way of ultrasound image segmentation. We believe that our method can provide doctors with reliable auxiliary diagnosis information in clinical practice.
Collapse
Affiliation(s)
- Xingtao Lin
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Xiaogen Zhou
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Tong Tong
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University; Imperial Vision Technology.
| | - Xingqing Nie
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Luoyan Wang
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Haonan Zheng
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Jing Li
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | | | - Shun Chen
- Fujian Medical University Union Hospital.
| | | | - Cong Chen
- Fujian Medical University Union Hospital
| | - Haiyan Jiang
- Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Min Du
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University
| | - Qinquan Gao
- College of Physics and Information Engineering, Fuzhou University; Fujian Key Lab of Medical Instrumentation & Pharmaceutical Technology, Fuzhou University; Imperial Vision Technology
| |
Collapse
|
38
|
Wu X, Xia L, Wang J, Wang C, Zhang Q, Zhu J, Rao Q, Cheng H, Liu Z, Y. Yin, Ai X, Gulina K, Zheng H, Luo X, Chang B, Li L, Liu H, Li Y, Zhu J. 79P Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
39
|
Jiang Y, Huang J, Tian K, Yi X, Zheng H, Zhu Y, Guo T, Ji X. Cross-regulome profiling of RNA polymerases highlights the regulatory role of polymerase III on mRNA transcription by maintaining local chromatin architecture. Genome Biol 2022; 23:246. [PMID: 36443871 PMCID: PMC9703767 DOI: 10.1186/s13059-022-02812-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Accepted: 11/07/2022] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Mammalian cells have three types of RNA polymerases (Pols), Pol I, II, and III. However, the extent to which these polymerases are cross-regulated and the underlying mechanisms remain unclear. RESULTS We employ genome-wide profiling after acute depletion of Pol I, Pol II, or Pol III to assess cross-regulatory effects between these Pols. We find that these enzymes mainly affect the transcription of their own target genes, while certain genes are transcribed by the other polymerases. Importantly, the most active type of crosstalk is exemplified by the fact that Pol III depletion affects Pol II transcription. Pol II genes with transcription changes upon Pol III depletion are enriched in diverse cellular functions, and Pol III binding sites are found near their promoters. However, these Pol III binding sites do not correspond to transfer RNAs. Moreover, we demonstrate that Pol III regulates Pol II transcription and chromatin binding of the facilitates chromatin transcription (FACT) complex to alter local chromatin structures, which in turn affects the Pol II transcription rate. CONCLUSIONS Our results support a model suggesting that RNA polymerases show cross-regulatory effects: Pol III affects local chromatin structures and the FACT-Pol II axis to regulate the Pol II transcription rate at certain gene loci. This study provides a new perspective for understanding the dysregulation of Pol III in various tissues affected by developmental diseases.
Collapse
Affiliation(s)
- Yongpeng Jiang
- grid.452723.50000 0004 7887 9190Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871 China
| | - Jie Huang
- grid.452723.50000 0004 7887 9190Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871 China
| | - Kai Tian
- grid.452723.50000 0004 7887 9190Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871 China
| | - Xiao Yi
- grid.494629.40000 0004 8008 9315Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,grid.494629.40000 0004 8008 9315Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,Westlake Omics (Hangzhou) Biotechnology Co., Ltd, Hangzhou, 310024 China
| | - Haonan Zheng
- grid.452723.50000 0004 7887 9190Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871 China
| | - Yi Zhu
- grid.494629.40000 0004 8008 9315Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,grid.494629.40000 0004 8008 9315Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,Westlake Omics (Hangzhou) Biotechnology Co., Ltd, Hangzhou, 310024 China
| | - Tiannan Guo
- grid.494629.40000 0004 8008 9315Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,grid.494629.40000 0004 8008 9315Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou, 310024 Zhejiang Province China ,Westlake Omics (Hangzhou) Biotechnology Co., Ltd, Hangzhou, 310024 China
| | - Xiong Ji
- grid.452723.50000 0004 7887 9190Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871 China
| |
Collapse
|
40
|
Li HX, Li BL, Wang TH, Zheng H, Yan T. [Double-edged sword of opioids in the treatment of cancer pain: hyperalgesia]. Zhonghua Yi Xue Za Zhi 2022; 102:3073-3079. [PMID: 36274592 DOI: 10.3760/cma.j.cn112137-20220321-00600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Hyperalgesia is an occult complication during the treatment of cancer pain, not only related to opioids, but also pertaining to the tumor itself and cancer therapeutic drugs. Yet it is often ignored by clinicians. Patients with cancer pain who were treated with opioids often have sensory abnormalities presented with reduced pain threshold and increased sensitivity to nociceptive stimuli. This phenomenon is clinically called opioid-induced hyperalgesia (OIH). However, due to the complexity of pathogenesis and the lack of clinical diagnostic criteria, the pain management of cancer patients is still facing great challenges. Therefore, this article focuses on the clinical diagnosis, pathogenesis, prevention and treatment of hyperalgesia related to cancer pain treatment, in order to provide a basis for optimal use of opioids in the future.
Collapse
Affiliation(s)
- H X Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - B L Li
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T H Wang
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - H Zheng
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - T Yan
- Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
41
|
Zheng H, Wang QQ, Xiong LL, Yu Y, Fei J, Ding Z. [Comparison of time series and case-crossover analyses in environmental epidemiology]. Zhonghua Yu Fang Yi Xue Za Zhi 2022; 56:1446-1451. [PMID: 36274612 DOI: 10.3760/cma.j.cn112150-20220415-00375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Time-series and case-crossover are two main study designs in environmental epidemiology. However, due to the differences in design principles and model construction between the two analyses, the results of the two analyses may not be consistent. Herein, we examined the short-term effect of cold spells on cardiovascular mortality in Nanjing using both time series and case-crossover analyses, aiming to provide a basis for the selection of appropriate research design in environmental epidemiology.
Collapse
Affiliation(s)
- H Zheng
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - Q Q Wang
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - L L Xiong
- Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China
| | - Y Yu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - J Fei
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| | - Z Ding
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
| |
Collapse
|
42
|
Fan SL, Shi Y, Zhang S, Wang H, Kong DJ, Ren JS, Zhou YH, Li JH, Wang ZL, Zheng H. [Preclinical evaluation of a veno-venous bypass device for liver transplantation based on the principle of magnetic levitation drive]. Zhonghua Wai Ke Za Zhi 2022; 60:930-938. [PMID: 36207982 DOI: 10.3760/cma.j.cn112139-20220622-00277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To explore the performance of a self-made venous-venous bypass (VVB) device for liver transplantation based on the principle of magnetic levitation drive. Methods: Experimental study was conducted from August 2020 to January 2022. Eight Bama minipigs underwent VVB of hepatic portal vein-femoral vein-internal jugular vein after occlusion of hepatic portal vein and inferior vena cava. The animals were divided into two groups according to the VVB devices used during VVB. A self-made VVB device was used in group A(n=5),and an imported VVB device was used in group B(n=3). The hemodynamic changes of the two groups of animals were compared at 6 time points including before vascular occlusion, during vascular occlusion, 30 minutes, 60 minutes, 90 minutes after the start of VVB, and 30 minutes after vascular opening. In addition,the changes of blood compatibility indexes,intestinal injury indexes,kidney injury indexes and internal environment indexes of the two groups of animals at each time point were compared. The independent samples t test was used for the quantitative data between the two groups with non-repeated measures,and the repeated measures analysis of variance was used for the quantitative data between the two groups with repeated measures. Results: During the VVB of the two devices,the venous drainage was sufficient,and the main manifestations were that the color of the intestine of the Bama miniature pig was ruddy, the peristalsis was normal, and the urine output was normal. There were no significant differences in hemodynamics,blood injure indexes,intestinal injury indexes,kidney injury indexes,neutropil gelatinase-associated lipocalin,and internal environment indexes(all P>0.05).The indexes at 30 minutes after vascular opening in the group A and the group B were as follows:mean arterial pressure were (71.0±7.7)mmHg(1 mmHg=0.133 kPa) and (74.0±8.7)mmHg,central venous pressure were (7.0±1.4)cmH2O(1 cmH2O=0.098 kPa) and (7.7±0.6)cmH2O,heart rate were (131±10) beats/minutes and (132±8)beats/minutes; red blood cell count were (6.43±0.89)×1012/L and (6.32±0.58)×1012/L,hemoglobin were (108.4±5.9)g/L and (110.0±3.5)g/L,free hemoglobin were (78.28±3.96)mg/L and (78.08±4.54)mg/L; intestinal fatty acid binding protein were (2.27±0.49)μg/L and (2.40±0.78)μg/L;creatinine were (68.30±9.77)μmol/L and (79.90±26.91)μmol/L,blood urea nitrogen were (3.94±1.39)mmol/L and (3.45±0.65)mmol/L;neutropil gelatinase-associated lipocalin were (4.02±0.53) μg/L and (3.86±0.23)μg/L;pH value were 7.27±0.04 and 7.23±0.03,lactic acid were (6.18±2.62)mmol/L and (4.30±0.50)mmol/L,concentrations of Na+ were (136.3±3.0)mmol/L and (137.6±1.6) mmol/L,concentrations of K+ were (3.89±0.42) mmol/L and (3.98±0.17)mmol/L,concentrations of Ca2+ were (1.40±0.03)mmol/L and(1.40±0.04)mmol/L;all indexes in the two group had no differences(all P>0.05). Conclusion: The self-made venous bypass device can be safely and effectively applied to VVB of Bama minipigs,and achieves the same performance as the imported venous bypass device.
Collapse
Affiliation(s)
- S L Fan
- The First Central Clinical School,Tianjin Medical University,Tianjin 300070,China
| | - Y Shi
- Organ Transplant Department,Tianjin First Central Hospital,Tianjin Medical University,Tianjin 300192,China
| | - S Zhang
- School of Medicine,Nankai University,Tianjin 300074,China
| | - H Wang
- The First Central Clinical School,Tianjin Medical University,Tianjin 300070,China
| | - D J Kong
- School of Medicine,Nankai University,Tianjin 300074,China
| | - J S Ren
- The First Central Clinical School,Tianjin Medical University,Tianjin 300070,China
| | - Y H Zhou
- The First Central Clinical School,Tianjin Medical University,Tianjin 300070,China
| | - J H Li
- The First Central Clinical School,Tianjin Medical University,Tianjin 300070,China
| | - Z L Wang
- Key Laboratory for Organ Transplantation,Tianjin First Central Hospital,Tianjin 300192,China
| | - H Zheng
- Key Laboratory for Organ Transplantation,Tianjin First Central Hospital,Tianjin 300192,China
| |
Collapse
|
43
|
Wang H, Li B, Zuo L, Wang B, Yan Y, Tian K, Zhou R, Wang C, Chen X, Jiang Y, Zheng H, Qin F, Zhang B, Yu Y, Liu CP, Xu Y, Gao J, Qi Z, Deng W, Ji X. The transcriptional coactivator RUVBL2 regulates Pol II clustering with diverse transcription factors. Nat Commun 2022; 13:5703. [PMID: 36171202 PMCID: PMC9519968 DOI: 10.1038/s41467-022-33433-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 09/16/2022] [Indexed: 11/10/2022] Open
Abstract
RNA polymerase II (Pol II) apparatuses are compartmentalized into transcriptional clusters. Whether protein factors control these clusters remains unknown. In this study, we find that the ATPase-associated with diverse cellular activities (AAA + ) ATPase RUVBL2 co-occupies promoters with Pol II and various transcription factors. RUVBL2 interacts with unphosphorylated Pol II in chromatin to promote RPB1 carboxy-terminal domain (CTD) clustering and transcription initiation. Rapid depletion of RUVBL2 leads to a decrease in the number of Pol II clusters and inhibits nascent RNA synthesis, and tethering RUVBL2 to an active promoter enhances Pol II clustering at the promoter. We also identify target genes that are directly linked to the RUVBL2-Pol II axis. Many of these genes are hallmarks of cancers and encode proteins with diverse cellular functions. Our results demonstrate an emerging activity for RUVBL2 in regulating Pol II cluster formation in the nucleus. RNA polymerase II (Pol II) transcription factories play a central role in gene expression and 3D chromatin organization. Here, the authors demonstrate that RUVBL2 directly regulates Pol II clustering at active gene promoters.
Collapse
Affiliation(s)
- Hui Wang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.,Department of Pathogenic Biology, Chengdu Medical College, Chengdu, 610500, China
| | - Boyuan Li
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Linyu Zuo
- Center for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China
| | - Bo Wang
- Biomedical Pioneering Innovation Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, Beijing Advanced Innovation Center for Genomics (ICG), Peking-Tsinghua Center for Life Sciences (CLS), School of Life Sciences, Peking University, Beijing, 100871, China
| | - Yan Yan
- Institute for TCM-X; MOE Key Laboratory of Bioinformatics; Bioinformatics Division, BNRist (Beijing National Research Center for Information Science and Technology); Department of Automation, Tsinghua University, Beijing, 100084, China.,Center for Synthetic and Systems Biology, Tsinghua University, Beijing, 100084, China
| | - Kai Tian
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Rong Zhou
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Chenlu Wang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Xizi Chen
- Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai, 200032, China
| | - Yongpeng Jiang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Haonan Zheng
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China
| | - Fangfei Qin
- Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, China
| | - Bin Zhang
- Departments of Pathology and Laboratory Medicine, and Pediatrics, University of Rochester Medical Center, 601 Elmwood Ave, Box 608, Rochester, NY, 14642, USA
| | - Yang Yu
- Key Laboratory of RNA Biology, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | - Chao-Pei Liu
- National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
| | - Yanhui Xu
- Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai, 200032, China
| | - Juntao Gao
- Institute for TCM-X; MOE Key Laboratory of Bioinformatics; Bioinformatics Division, BNRist (Beijing National Research Center for Information Science and Technology); Department of Automation, Tsinghua University, Beijing, 100084, China.,Center for Synthetic and Systems Biology, Tsinghua University, Beijing, 100084, China
| | - Zhi Qi
- Center for Quantitative Biology, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China
| | - Wulan Deng
- Biomedical Pioneering Innovation Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, Beijing Advanced Innovation Center for Genomics (ICG), Peking-Tsinghua Center for Life Sciences (CLS), School of Life Sciences, Peking University, Beijing, 100871, China
| | - Xiong Ji
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
| |
Collapse
|
44
|
Nie X, Zhou X, Tong T, Lin X, Wang L, Zheng H, Li J, Xue E, Chen S, Zheng M, Chen C, Du M. Corrigendum: N-Net: A novel dense fully convolutional neural network for thyroid nodule segmentation. Front Neurosci 2022; 16:1034239. [PMID: 36203803 PMCID: PMC9532001 DOI: 10.3389/fnins.2022.1034239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Accepted: 09/02/2022] [Indexed: 11/21/2022] Open
Affiliation(s)
- Xingqing Nie
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Xiaogen Zhou
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Tong Tong
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
- Imperial Vision Technology, Fuzhou, China
- *Correspondence: Tong Tong
| | - Xingtao Lin
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Luoyan Wang
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Haonan Zheng
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Jing Li
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| | - Ensheng Xue
- Fujian Medical Ultrasound Research Institute, Fuzhou, China
- Department of Ultrasound, Fujian Medical University Union Hospital, Fuzhou, China
| | - Shun Chen
- Fujian Medical Ultrasound Research Institute, Fuzhou, China
- Department of Ultrasound, Fujian Medical University Union Hospital, Fuzhou, China
- Shun Chen
| | - Meijuan Zheng
- Fujian Medical Ultrasound Research Institute, Fuzhou, China
- Department of Ultrasound, Fujian Medical University Union Hospital, Fuzhou, China
| | - Cong Chen
- Fujian Medical Ultrasound Research Institute, Fuzhou, China
- Department of Ultrasound, Fujian Medical University Union Hospital, Fuzhou, China
| | - Min Du
- College of Physics and Information Engineering, Fuzhou University, Fuzhou, China
- Fujian Key Lab of Medical Instrumentation and Pharmaceutical Technology, Fuzhou University, Fuzhou, China
| |
Collapse
|
45
|
Li Y, Huang J, Zhu J, Bao L, Wang H, Jiang Y, Tian K, Wang R, Zheng H, Duan W, Lai W, Yi X, Zhu Y, Guo T, Ji X. Targeted protein degradation reveals RNA Pol II heterogeneity and functional diversity. Mol Cell 2022; 82:3943-3959.e11. [PMID: 36113479 DOI: 10.1016/j.molcel.2022.08.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 07/14/2022] [Accepted: 08/18/2022] [Indexed: 10/14/2022]
Abstract
RNA polymerase II (RNA Pol II) subunits are thought to be involved in various transcription-associated processes, but it is unclear whether they play different regulatory roles in modulating gene expression. Here, we performed nascent and mature transcript sequencing after the acute degradation of 12 mammalian RNA Pol II subunits and profiled their genomic binding sites and protein interactomes to dissect their molecular functions. We found that RNA Pol II subunits contribute differently to RNA Pol II cellular localization and transcription processes and preferentially regulate RNA processing (such as RNA splicing and 3' end maturation). Genes sensitive to the depletion of different RNA Pol II subunits tend to be involved in diverse biological functions and show different RNA half-lives. Sequences, associated protein factors, and RNA structures are correlated with RNA Pol II subunit-mediated differential gene expression. These findings collectively suggest that the heterogeneity of RNA Pol II and different genes appear to depend on some of the subunits.
Collapse
Affiliation(s)
- Yuanjun Li
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Jie Huang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Junyi Zhu
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Lijun Bao
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Hui Wang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Yongpeng Jiang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Kai Tian
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Rui Wang
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Haonan Zheng
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - WenJia Duan
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Weifeng Lai
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
| | - Xiao Yi
- Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China
| | - Yi Zhu
- Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China
| | - Tiannan Guo
- Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China
| | - Xiong Ji
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
| |
Collapse
|
46
|
Ma X, Liu Y, Chen ZH, Zhang Y, Dong H, Song JQ, Jin Y, Li MQ, Kang LL, He RX, Ding Y, Li DX, Zheng H, Sun LY, Zhu ZJ, Yang YL, Cao Y. [Phenotypes and genotypes of 78 patients with propionic acidemia]. Zhonghua Yu Fang Yi Xue Za Zhi 2022; 56:1263-1271. [PMID: 36207890 DOI: 10.3760/cma.j.cn112150-20220620-00630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: Propionic acidemia is a rare inherited metabolic disorder caused by propionyl CoA carboxylase (PCC) deficiency. This study aims to analyze the clinical characteristics and gene variations of Chinese patients with propionic acidemia, and to explore the correlation between clinical phenotypes and genotypes. Methods: Single-center, retrospective and observational study. Seventy-eight patients of propionic acidemia (46 males and 32 females) from 20 provinces and autonomous regions were admitted from January 2007 to April 2022. Their age of initial diagnosis ranged from 7 days to 15 years. The clinical manifestations, biochemical and metabolic abnormalities, genetic variations, diagnosis, treatment and outcome were studied. Chi-Square test or Mann-Whitney U test were used for statistical analysis. Results: Among 78 cases, 6 (7.7%) were identified by newborn screening; 72 (92.3%) were clinically diagnosed after onset, and the age of onset was 2 hours after birth to 15 years old; 32 cases had early-onset disease and 40 cases had late-onset disease. The initial manifestations included lethargy, hypotonia, vomiting, feeding difficulties, developmental delay, epilepsy, and coma. Among the 74 cases who accepted gene analysis, 35 (47.3%) had PCCA variants and 39 (52.7%) had PCCB variants. A total of 39 PCCA variants and 32 PCCB variants were detected, among which c.2002G>A and c.229C>T in PCCA and c.838dupC and c.1087T>C in PCCB were the most common variants in this cohort. The variants c.1228C>T and c.1283C>T in PCCB may be related to early-onset type. The variants c.838dupC, c.1127G>T and c.1316A>G in PCCB, and c.2002G>A in PCCA may be related to late-onset disease. Six patients detected by newborn screening and treated at asymptomatic stage developed normal. The clinically diagnosed 72 cases had varied complications. 10 (12.8%) cases of them died. 62 patients improved after metabolic therapy by L-carnitine and diet. Six patients received liver transplantation because of recurrent metabolic crisis. Their clinical symptoms were markedly improved. Conclusion: The clinical manifestations of propionic acidemia are complex and lack of specificity. Newborn screening and high-risk screening are keys for early treatment and better outcome. The correlation between the genotype and phenotype of propionic acidemia is unclear, but certain variants may be associated with early-onset or late-onset propionic acidemia.
Collapse
Affiliation(s)
- X Ma
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - Y Liu
- Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029,China
| | - Z H Chen
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - Y Zhang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - H Dong
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - J Q Song
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - Y Jin
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - M Q Li
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - L L Kang
- Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - R X He
- Department of Respiratory, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - Y Ding
- Department of Endocrinology and Genetic, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
| | - D X Li
- Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated of Zhengzhou University, Zhengzhou 450053, China
| | - H Zheng
- Department of Pediatrics, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450099, China
| | - L Y Sun
- Department of General Surgery, Beijing Friendship Hospital of Capital Medical University, Beijing 100050, China
| | - Z J Zhu
- Department of General Surgery, Beijing Friendship Hospital of Capital Medical University, Beijing 100050, China
| | - Y L Yang
- Department of Pediatrics, Peking University First Hospital, Beijing 100034,China
| | - Yongtong Cao
- Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing 100029,China
| |
Collapse
|
47
|
Zheng H, Li MS, Wu D, Yan TT, An ZJ, Li YX. [Interpretation of defeating meningitis by 2030: a global road map]. Zhonghua Yu Fang Yi Xue Za Zhi 2022; 56:1348-1352. [PMID: 36207902 DOI: 10.3760/cma.j.cn112150-20220217-00148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Meningitis is a life-threatening disease. In order to reduce its threat to public health, the World Health Assembly indorsed a resolution in 2020 for urgent global action to prevent and control meningitis. Defeating Meningitis by 2030: a Global Roadmap was officially launched by the World Health Organization in 2021. We interpreted some key information of the roadmap from the aspects of coverage, objectives and pillar strategies, providing ideas for further strengthening the prevention and control of bacterial meningitis in China.
Collapse
Affiliation(s)
- H Zheng
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - M S Li
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - D Wu
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - T T Yan
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Z J An
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Y X Li
- Department of National Immunization Program,Chinese Center for Disease Control and Prevention, Beijing 100050, China
| |
Collapse
|
48
|
Cheng W, Zhou Y, Chu X, Huang S, Zheng X, Zheng H. Efecto de la mitomicina en comparación con la gemcitabina intravesical en el tratamiento del cáncer de vejiga sin invasión muscular: metaanálisis. Actas Urol Esp 2022. [DOI: 10.1016/j.acuro.2022.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Cui CL, Li Z, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Lian B, Wang X, Tian H, Si L, Chi Z, Sheng X, Lai Y, Sun T, Zhang Q, Kong Y, Guo J. 796P Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
50
|
Yu Y, Huang D, Gao B, Zhao J, Hu Y, Zhuang W, Kao S, Xu W, Yao Y, Yang TY, Lee Y, Kim JS, Shiah HS, Wang R, Zheng H, Tan W, Gao R, Kim H, Lu S. 1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|